<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T03:53:46Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:8790668" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:8790668</identifier>
        <datestamp>2022-02-07</datestamp>
        <setSpec>jamasd</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">JAMA Netw Open</journal-id>
              <journal-id journal-id-type="iso-abbrev">JAMA Netw Open</journal-id>
              <journal-title-group>
                <journal-title>JAMA Network Open</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2574-3805</issn>
              <publisher>
                <publisher-name>American Medical Association</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC8790668</article-id>
              <article-id pub-id-type="pmcid">PMC8790668</article-id>
              <article-id pub-id-type="pmc-uid">8790668</article-id>
              <article-id pub-id-type="pmid">35076703</article-id>
              <article-id pub-id-type="pmid">35076703</article-id>
              <article-id pub-id-type="doi">10.1001/jamanetworkopen.2021.44178</article-id>
              <article-id pub-id-type="publisher-id">zoi211221</article-id>
              <article-categories>
                <subj-group subj-group-type="category" specific-use="electronic">
                  <subject>Research</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Original Investigation</subject>
                </subj-group>
                <subj-group subj-group-type="online-only">
                  <subject>Online Only</subject>
                </subj-group>
                <subj-group subj-group-type="subject-area">
                  <subject>Neurology</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy</article-title>
                <subtitle>A 30-Month Nonrandomized Controlled Open-Label Extension Trial</subtitle>
                <alt-title alt-title-type="headline">Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy</alt-title>
                <alt-title alt-title-type="running-head">Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy</alt-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" corresp="yes">
                  <name>
                    <surname>Mah</surname>
                    <given-names>Jean K.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="zoi211221aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Clemens</surname>
                    <given-names>Paula R.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="zoi211221aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Guglieri</surname>
                    <given-names>Michela</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="zoi211221aff3" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Smith</surname>
                    <given-names>Edward C.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="zoi211221aff4" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Finkel</surname>
                    <given-names>Richard S.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="zoi211221aff5" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                  <xref rid="zoi211221aff6" ref-type="aff">
                    <sup>6</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Tulinius</surname>
                    <given-names>Mar</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="zoi211221aff7" ref-type="aff">
                    <sup>7</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Nevo</surname>
                    <given-names>Yoram</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="zoi211221aff8" ref-type="aff">
                    <sup>8</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ryan</surname>
                    <given-names>Monique M.</given-names>
                  </name>
                  <degrees>MMed</degrees>
                  <degrees>BS</degrees>
                  <xref rid="zoi211221aff9" ref-type="aff">
                    <sup>9</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Webster</surname>
                    <given-names>Richard</given-names>
                  </name>
                  <degrees>MBBS</degrees>
                  <xref rid="zoi211221aff10" ref-type="aff">
                    <sup>10</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Castro</surname>
                    <given-names>Diana</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="zoi211221aff11" ref-type="aff">
                    <sup>11</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kuntz</surname>
                    <given-names>Nancy L.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="zoi211221aff12" ref-type="aff">
                    <sup>12</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>McDonald</surname>
                    <given-names>Craig M.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="zoi211221aff13" ref-type="aff">
                    <sup>13</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Damsker</surname>
                    <given-names>Jesse M.</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="zoi211221aff14" ref-type="aff">
                    <sup>14</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Schwartz</surname>
                    <given-names>Benjamin D.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <degrees>PhD</degrees>
                  <xref rid="zoi211221aff15" ref-type="aff">
                    <sup>15</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Mengle-Gaw</surname>
                    <given-names>Laurel J.</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="zoi211221aff15" ref-type="aff">
                    <sup>15</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Jackowski</surname>
                    <given-names>Stefan</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="zoi211221aff16" ref-type="aff">
                    <sup>16</sup>
                  </xref>
                  <xref rid="zoi211221aff17" ref-type="aff">
                    <sup>17</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Stimpson</surname>
                    <given-names>Georgia</given-names>
                  </name>
                  <degrees>MS</degrees>
                  <xref rid="zoi211221aff18" ref-type="aff">
                    <sup>18</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ridout</surname>
                    <given-names>Deborah A.</given-names>
                  </name>
                  <degrees>MS</degrees>
                  <xref rid="zoi211221aff18" ref-type="aff">
                    <sup>18</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ayyar-Gupta</surname>
                    <given-names>Vandana</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="zoi211221aff18" ref-type="aff">
                    <sup>18</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Baranello</surname>
                    <given-names>Giovanni</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <degrees>PhD</degrees>
                  <xref rid="zoi211221aff18" ref-type="aff">
                    <sup>18</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Manzur</surname>
                    <given-names>Adnan Y.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="zoi211221aff18" ref-type="aff">
                    <sup>18</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Muntoni</surname>
                    <given-names>Francesco</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="zoi211221aff18" ref-type="aff">
                    <sup>18</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Gordish-Dressman</surname>
                    <given-names>Heather</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="zoi211221aff19" ref-type="aff">
                    <sup>19</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Leinonen</surname>
                    <given-names>Mika</given-names>
                  </name>
                  <degrees>MS</degrees>
                  <xref rid="zoi211221aff20" ref-type="aff">
                    <sup>20</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ward</surname>
                    <given-names>Leanne M.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="zoi211221aff16" ref-type="aff">
                    <sup>16</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Hoffman</surname>
                    <given-names>Eric P.</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="zoi211221aff14" ref-type="aff">
                    <sup>14</sup>
                  </xref>
                  <xref rid="zoi211221aff21" ref-type="aff">
                    <sup>21</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Dang</surname>
                    <given-names>Utkarsh J.</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="zoi211221aff21" ref-type="aff">
                    <sup>21</sup>
                  </xref>
                  <xref rid="zoi211221aff22" ref-type="aff">
                    <sup>22</sup>
                  </xref>
                </contrib>
                <on-behalf-of>for the NorthStar UK Network and CINRG DNHS Investigators</on-behalf-of>
              </contrib-group>
              <aff id="zoi211221aff1"><label>1</label>Alberta Children’s Hospital Research Institute, University of Calgary, Calgary, Canada</aff>
              <aff id="zoi211221aff2"><label>2</label>University of Pittsburgh and Department of Veterans Affairs Medical Center, Pittsburgh, Pennsylvania</aff>
              <aff id="zoi211221aff3"><label>3</label>John Walton Muscular Dystrophy Research Centre, Newcastle University, Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom</aff>
              <aff id="zoi211221aff4"><label>4</label>Duke University Medical Center, Durham, North Carolina</aff>
              <aff id="zoi211221aff5"><label>5</label>Nemours Children’s Hospital, Orlando, Florida</aff>
              <aff id="zoi211221aff6"><label>6</label>St. Jude Children’s Research Hospital, Memphis, Tennessee</aff>
              <aff id="zoi211221aff7"><label>7</label>Queen Silvia Children’s Hospital, Gothenburg, Sweden</aff>
              <aff id="zoi211221aff8"><label>8</label>Schneider Children’s Medical Center of Israel, Tel Aviv University, Petah Tikvah, Israel</aff>
              <aff id="zoi211221aff9"><label>9</label>Royal Children’s Hospital and Murdoch Children’s Research Institute, Melbourne, Australia</aff>
              <aff id="zoi211221aff10"><label>10</label>The Children’s Hospital at Westmead, Sydney, Australia</aff>
              <aff id="zoi211221aff11"><label>11</label>University of Texas Southwestern, Dallas</aff>
              <aff id="zoi211221aff12"><label>12</label>Ann and Robert H. Lurie Children’s Hospital, Chicago, Illinois</aff>
              <aff id="zoi211221aff13"><label>13</label>University of California Davis, Sacramento</aff>
              <aff id="zoi211221aff14"><label>14</label>ReveraGen BioPharma, Rockville, Maryland</aff>
              <aff id="zoi211221aff15"><label>15</label>Camden Group, St Louis, Missouri</aff>
              <aff id="zoi211221aff16"><label>16</label>Children’s Hospital of Eastern Ontario, Ottawa, Ontario, Canada</aff>
              <aff id="zoi211221aff17"><label>17</label>University of Saskatchewan, Saskatoon, Canada</aff>
              <aff id="zoi211221aff18"><label>18</label>Dubowitz Neuromuscular Centre, University College London Great Ormond Street Institute of Child Health, London, United Kingdom</aff>
              <aff id="zoi211221aff19"><label>19</label>Children’s National Hospital, Washington, District of Columbia</aff>
              <aff id="zoi211221aff20"><label>20</label>Santhera Pharmaceuticals, Pratteln, Switzerland</aff>
              <aff id="zoi211221aff21"><label>21</label>Binghamton University-State University of New York, Binghamton</aff>
              <aff id="zoi211221aff22"><label>22</label>Carleton University, Ottawa, Canada</aff>
              <author-notes>
                <title>Article Information</title>
                <p><bold>Accepted for Publication:</bold> November 19, 2021.</p>
                <p content-type="published-online"><bold>Published:</bold> January 25, 2022. <?xpp bx;1?>doi:<uri content-type="doi">10.1001/jamanetworkopen.2021.44178</uri></p>
                <p content-type="open-access-note"><bold>Open Access:</bold> This is an open access article distributed under the terms of the <ext-link xlink:href="https://jamanetwork.com/pages/cc-by-nc-nd-license-permissions" ext-link-type="uri">CC-BY-NC-ND License</ext-link>. © 2022 Mah JK et al. <italic>JAMA Network Open</italic>.</p>
                <corresp id="zoi211221cor1"><bold>Corresponding Author</bold>: Jean K. Mah, MD, Alberta Children’s Hospital Research Institute, University of Calgary, 28 Oki Dr NW, Calgary, Alberta, Canada T3B 6A8 (<email xlink:href="jean.mah@ahs.ca">jean.mah@ahs.ca</email>).</corresp>
                <p content-type="author-contributions"><bold>Author Contributions:</bold> Dr Dang had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.</p>
                <p><italic>Concept and design:</italic> Clemens, Guglieri, Finkel, McDonald, Schwartz, Mengle-Gaw, Leinonen, Hoffman, Dang.</p>
                <p><italic>Acquisition, analysis, or interpretation of data:</italic> All authors.</p>
                <p><italic>Drafting of the manuscript:</italic> Mah, McDonald, Leinonen, Hoffman, Dang.</p>
                <p><italic>Critical revision of the manuscript for important intellectual content:</italic> Mah, Clemens, Guglieri, Smith, Finkel, Tulinius, Nevo, Ryan, Webster, Castro, Kuntz, Damsker, Schwartz, Mengle-Gaw, Jackowski, Stimpson, Ridout, Ayyar-Gupta, Baranello, Manzur, Muntoni, Gordish-Dressman, Leinonen, Ward, Hoffman, Dang.</p>
                <p><italic>Statistical analysis:</italic> Stimpson, Gordish-Dressman, Leinonen, Hoffman, Dang.</p>
                <p><italic>Obtained funding:</italic> Clemens, Guglieri, Hoffman.</p>
                <p><italic>Administrative, technical, or material support:</italic> Mah, Clemens, Finkel, Ryan, McDonald, Damsker, Schwartz, Mengle-Gaw, Jackowski, Ayyar-Gupta, Manzur, Ward, Hoffman.</p>
                <p><italic>Supervision:</italic> Mah, Clemens, Tulinius, Ryan, Castro, McDonald, Ridout, Baranello, Hoffman.</p>
                <p content-type="COI-statement"><bold>Conflict of Interest Disclosures:</bold> Dr Mah reported receiving grants from ReveraGen BioPharma during the conduct of the study; grants from Pfizer, Italfarmaco, Sarepta, Catabasis, Roche, Biogen, Novartis, NS Pharma, PTC Therapeutics, and Alberta Children's Hospital Foundation; and personal fees from PTC Therapeutics, Biogen, and Roche outside the submitted work. Dr Clemens reported serving as a board member for Therapeutic Research in Neuromuscular Disorders Solutions (TRINDS); receiving grants from the National Institutes of Health (NIH), NS Pharma, Amicus, Sanofi, Spark, and Muscular Dystrophy Association; receiving research support through a donation from the Foundation to Eradicate Duchenne to the University of Pittsburgh; and receiving personal fees from Epirium during the conduct of the study outside the submitted work. Dr Guglieri reported receiving data management support from North Star Network during the conduct of the study; grants from the NIH, European Committee H2020, Duchenne Muscular Dystrophy UK, and Sarepta (funding through Translational Research in Europe: Assessment and Treatment of Neuromuscular Disorders); personal fees from Sarepta; and travel fees from Santhera outside the submitted work and serving as principal or chief investigator or clinical investigator for clinical trials sponsored by Pfizer, Italfarmaco, Summit, Santhera, Roche, and PTC Therapeutics. Dr Smith reported receiving grants for partial salary support from Reveragen BioPharma as principal investigator during the conduct of the study. Dr Finkel reported receiving grants from ReveraGen BioPharma during the conduct of the study and grants from Catabasis and Sarepta outside the submitted work. Dr Webster reported receiving research funding from ReveraGen BioPharma during the conduct of the study. Dr Kuntz reported receiving grants from Astellas Gene Therapies, Biogen, Genentech, Novartis, and Sarepta; personal fees from Biogen, Genentech, Novartis, and Sarepta; and data safety monitoring board services from Sarepta during the conduct of the study. Dr McDonald reported receiving grants from the NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), US Department of Defense, National Institute on Disability Independent Living and Rehabilitation Research, and Parent Project Muscular Dystrophy and personal fees from Astellas, BioMarin, Epirium Bio (formerly Capricor), Catabasis, Entrada Therapeutics, Avidity Therapeutics, Edgewise Therapeutics, FibroGen, Hoffmann La Roche, Marathon, Pfizer, Santhera Pharmaceuticals, Saraepta Therapeutics, and PTC Therapeutics outside the submitted work. Dr Damsker reported being an employee and shareholder of ReveraGen BioPharma. Dr Schwartz reported receiving personal fees from ReveraGen Biopharma during the conduct of the study and personal fees from RegenXBio and TRINDS outside the submitted work. Dr Mengle-Gaw reported receiving personal fees from ReveraGen BioPharma during the conduct of the study and personal fees from RegenXBio outside the submitted work. Dr Baranello reported receiving personal fees from Roche, serving as principal investigator in clinical trials for Pfizer and Reveragen, receiving grants from Sarepta via the Dubowitz Neuromuscular Centre, and serving as an investigator in a clinical trial for NS Pharma outside the submitted work. Dr Manzur reported receiving grants from NorthStar Clinical Network during the conduct of the study and serving as clinical lead for Northstar Clinical Network UK. Dr Muntoni reported receiving grants from Muscular Dystrophy UK North Star Consortium during the conduct of the study; grants from the NIH Research Great Ormond Street Hospital-ICH Biomedical Research Centre, Genethon, and Sarepta; and personal fees from Dyne Therapeutics, Pfizer, and Sarepta outside the submitted work. Dr Gordish-Dressman reported receiving personal fees from TRINDS during the conduct of the study and co-owning TRINDS outside the submitted work. Dr Ward reported receiving grants from ReveraGen BioPharma via the Children's Hospital of Eastern Ontario (CHEO) Research Institute during the conduct of the study and grants from Amgen, Novartis, and PTC Therapeutics via the CHEO Research Institute outside the submitted work. Dr Hoffman reported receiving salary as chief executive officer and owning stock from ReveraGen BioPharma, serving as a board member for TRINDS, receiving grants from the NIH National Institute of Neurological Disorders and Stroke during the conduct of the study; serving as vice president and owning stock for Agada BioSciences outside the submitted work; and owning a patent issued to ReveraGen BioPharma. Dr Dang reported receiving grants from the Foundation to Eradicate Duchenne and personal fees from ReveraGen BioPharma during the conduct of the study and grants from the NIH NIAMS outside the submitted work. No other disclosures were reported.</p>
                <p content-type="funding-statement"><bold>Funding/Support:</bold> This work was funded by grants R44NS095423 from the National Institutes of Health (NIH) National Institute of Neurological Disorders and Stroke to Drs Hoffman and Clemens, 5U54HD090254 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development to Dr Hoffman, and U34AR068616 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases to Dr Clemens and grant agreement number 667078 from the European Commission Horizons 2020 to Dr Guglieri. Support for the vamorolone development program was provided by the Muscular Dystrophy Association, Foundation to Eradicate Duchenne, Parent Project Muscular Dystrophy, Duchenne UK (formed by Joining Jack and Duchenne Children’s Trust), Duchenne Research Fund, Save Our Sons, Michael’s Cause, Pietro’s Fight, Alex’s Wish, Ryan’s Quest, and Cure Duchenne. Vamorolone was developed through a partnership with the NIH National Center for Advancing Translational Sciences Therapeutics for Rare and Neglected Diseases program, with support for drug production, formulation, and toxicology studies. The Cooperative International Neuromuscular Research Group Duchenne Natural History Study was supported by grants H133B031118 and H133B090001 from the US Department of Education National Institute on Disability and Rehabilitation Research, W81XWH-12-1-0417 from the US Department of Defense, and R01AR061875 from the NIH NIAMS and Parent Project Muscular Dystrophy. The UK NorthStar Clinical Network for Duchenne Muscular Dystrophy is funded by Muscular Dystrophy UK.</p>
                <p><bold>Role of the Funder/Sponsor:</bold> The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.</p>
                <p><bold>Group Information:</bold> NorthStar UK Network and CINRG DNHS Investigators are listed in <xref rid="note-ZOI211221-1-s" ref-type="supplementary-material">Supplement 3</xref>.</p>
                <p content-type="data-sharing-statement"><bold>Data Sharing Statement:</bold> See <xref rid="note-ZOI211221-1-s" ref-type="supplementary-material">Supplement 4</xref>.</p>
                <p><bold>Additional Contributions:</bold> We would like to thank all patients with Duchenne muscular dystrophy and their families for participating in the research studies, as well as the study coordinators, clinical evaluators, and Therapeutic Research in Neuromuscular Disorders Solutions staff for the vamorolone long-term extension trial.</p>
              </author-notes>
              <pub-date pub-type="epub" iso-8601-date="2022-01-25T10:00">
                <day>25</day>
                <month>1</month>
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="collection">
                <month>1</month>
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>25</day>
                <month>1</month>
                <year>2022</year>
              </pub-date>
              <!--PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>.-->
              <volume>5</volume>
              <issue>1</issue>
              <elocation-id>e2144178</elocation-id>
              <history>
                <date date-type="received">
                  <day>3</day>
                  <month>9</month>
                  <year>2021</year>
                </date>
                <date date-type="accepted">
                  <day>19</day>
                  <month>11</month>
                  <year>2021</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>Copyright 2022 Mah JK et al. <italic>JAMA Network Open</italic>.</copyright-statement>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
                  <license-p>This is an open access article distributed under the terms of the CC-BY-NC-ND License.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf-version" xlink:href="jamanetwopen-e2144178.pdf">jamanetwopen-e2144178.pdf</self-uri>
              <self-uri content-type="silverchair" xlink:href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2021.44178"/>
              <abstract abstract-type="teaser" specific-use="electronic">
                <p>This nonrandomized controlled trial examines efficacy of vamorolone treatment for Duchenne muscular dystrophy among boys compared with glucocorticoid treatment.</p>
              </abstract>
              <abstract abstract-type="key-points">
                <title>Key Points</title>
                <sec id="ab-zoi211221-1">
                  <title>Question</title>
                  <p>Is long-term treatment with vamorolone associated with sustained disease modification and decrease of glucocorticoid-associated adverse outcomes among patients with Duchenne muscular dystrophy (DMD)?</p>
                </sec>
                <sec id="ab-zoi211221-2">
                  <title>Findings</title>
                  <p>In this nonrandomized controlled trial of 46 boys with DMD, higher-dose vamorolone treatment for up to 30 months was not associated with a change in time to stand velocity. Vamorolone was associated with continued disease-modification and similar efficacy compared with glucocorticoid treatment from 2 historical control cohorts, and long-term vamorolone treatment was associated with decreased adverse outcomes compared with traditional glucocorticoid therapy.</p>
                </sec>
                <sec id="ab-zoi211221-3">
                  <title>Meaning</title>
                  <p>These findings suggest that vamorolone may have potential as a standard of care disease-modifying treatment for boys with DMD.</p>
                </sec>
              </abstract>
              <abstract>
                <sec id="ab-zoi211221-4">
                  <title>Importance</title>
                  <p>Vamorolone is a synthetic steroidal drug with potent anti-inflammatory properties. Initial open-label, multiple ascending dose-finding studies of vamorolone among boys with Duchenne muscular dystrophy (DMD) found significant motor function improvement after 6 months treatment in higher-dose (ie, ≥2.0 mg/kg/d) groups.</p>
                </sec>
                <sec id="ab-zoi211221-5">
                  <title>Objective</title>
                  <p>To investigate outcomes after 30 months of open-label vamorolone treatment.</p>
                </sec>
                <sec id="ab-zoi211221-6">
                  <title>Design, Setting, and Participants</title>
                  <p>This nonrandomized controlled trial was conducted by the Cooperative International Neuromuscular Research Group at 11 US and non-US study sites. Participants were 46 boys ages 4.5 to 7.5 years with DMD who completed the 6-month dose-finding study. Data were analyzed from July 2020 through November 2021.</p>
                </sec>
                <sec id="ab-zoi211221-7">
                  <title>Interventions</title>
                  <p>Participants were enrolled in a 24-month, long-term extension (LTE) study with vamorolone dose escalated to 2.0 or 6.0 mg/kg/d.</p>
                </sec>
                <sec id="ab-zoi211221-8">
                  <title>Main Outcomes and Measures</title>
                  <p>Change in time-to-stand (TTSTAND) velocity from dose-finding baseline to end of LTE study was the primary outcome. Efficacy assessments included timed function tests, 6-minute walk test, and NorthStar Ambulatory Assessment (NSAA). Participants with DMD treated with glucocorticoids from the Duchenne Natural History Study (DNHS) and NorthStar United Kingdom (NSUK) Network were matched and compared with participants in the LTE study receiving higher doses of vamorolone.</p>
                </sec>
                <sec id="ab-zoi211221-9">
                  <title>Results</title>
                  <p>Among 46 boys with DMD who completed the dose-finding study, 41 boys (mean [SD] age, 5.33 [0.96] years) completed the LTE study. Among 21 participants treated with higher-dose (ie, ≥2.0 mg/kg/d) vamorolone consistently throughout the 6-month dose-finding and 24-month LTE studies with data available at 30 months, there was a decrease in mean (SD) TTSTAND velocity from baseline to 30 months (0.206 [0.070] rises/s vs 0.189 (0.124) rises/s), which was not a statistically significant change (−0.011 rises/s; CI, −0.068 to 0.046 rises/s). There were no statistically significant differences between participants receiving higher-dose vamorolone and matched participants in the historical control groups receiving glucocorticoid treatment (75 patients in DNHS and 110 patients in NSUK) over a 2-year period in NSAA total score change (0.22 units vs NSUK; 95% CI, −4.48 to 4.04]; <italic>P</italic> = .92), body mass index <italic>z</italic> score change (0.002 vs DNHS SD/mo; 95% CI, −0.006 to 0.010; <italic>P</italic> = .58), or timed function test change. Vamorolone at doses up to 6.0 mg/kg/d was well tolerated, with 5 of 46 participants discontinuing prematurely and for reasons not associated with study drug. Participants in the DNHS treated with glucocorticoids had significant growth delay in comparison with participants treated with vamorolone who had stable height percentiles (0.37 percentile/mo; 95% CI, 0.23 to 0.52 percentile/mo) over time.</p>
                </sec>
                <sec id="ab-zoi211221-10">
                  <title>Conclusions and Relevance</title>
                  <p>This study found that vamorolone treatment was not associated with a change in TTSTAND velocity from baseline to 30 months among boys with DMD aged 4 to 7 years at enrollment. Vamorolone was associated with maintenance of muscle strength and function up to 30 months, similar to standard of care glucocorticoid therapy, and improved height velocity compared with growth deceleration associated with glucocorticoid treatment, suggesting that vamorolone may be an attractive candidate for treatment of DMD.</p>
                </sec>
                <sec id="ab-zoi211221-11">
                  <title>Trial Registration</title>
                  <p>ClinicalTrials.gov Identifier: <ext-link xlink:href="https://clinicaltrials.gov/ct2/show/NCT03038399" ext-link-type="uri">NCT03038399</ext-link></p>
                </sec>
              </abstract>
            </article-meta>
          </front>
          <body>
            <sec id="H1-1-ZOI211221">
              <title>Introduction</title>
              <p>Duchenne muscular dystrophy (DMD) is a rapidly progressive X-linked recessive disease, with symptom onset before age 6 years in boys. It is the most common form of muscular dystrophy in childhood, occurring among 1 in 3600 to 9300 male newborns worldwide.<sup><xref rid="zoi211221r1" ref-type="bibr">1</xref></sup> The disease is caused by variants in the <italic>DMD</italic> gene, which codes for the dystrophin protein.<sup><xref rid="zoi211221r2" ref-type="bibr">2</xref></sup> The lack of dystrophin results in membrane fragility, necrosis, inflammation, and progressive muscle atrophy.<sup><xref rid="zoi211221r3" ref-type="bibr">3</xref></sup> Aberrant intracellular signaling cascades also contribute to DMD pathophysiology. Upregulated inflammatory gene expression and activated immune cell infiltrates, at least partially mediated by nuclear factor κ light chain enhancer of activated B cells (NF-κB) activation, are evident during early disease stages and play a significant role in disease progression.<sup><xref rid="zoi211221r3" ref-type="bibr">3</xref>,<xref rid="zoi211221r4" ref-type="bibr">4</xref>,<xref rid="zoi211221r5" ref-type="bibr">5</xref></sup> NF-κB regulates expression of numerous inflammatory genes in immune cells and muscle fibers,<sup><xref rid="zoi211221r6" ref-type="bibr">6</xref>,<xref rid="zoi211221r7" ref-type="bibr">7</xref>,<xref rid="zoi211221r8" ref-type="bibr">8</xref>,<xref rid="zoi211221r9" ref-type="bibr">9</xref></sup> and the infiltration and activation of these cells can trigger muscle cell death.<sup><xref rid="zoi211221r10" ref-type="bibr">10</xref>,<xref rid="zoi211221r11" ref-type="bibr">11</xref></sup></p>
              <p>Despite scientific advances, the only medications that have consistently demonstrated efficacy in clinical trials for DMD are glucocorticoids (GCs), such as prednisone and deflazacort.<sup><xref rid="zoi211221r12" ref-type="bibr">12</xref>,<xref rid="zoi211221r13" ref-type="bibr">13</xref>,<xref rid="zoi211221r14" ref-type="bibr">14</xref>,<xref rid="zoi211221r15" ref-type="bibr">15</xref></sup> Most gene-targeted disease-modifying technologies that are currently in development or have been recently approved focus on subsets of dystrophin variants and therefore do not address the unmet need among all individuals with DMD. Moreover, these treatments are prescribed in combination with and not as alternatives to GCs. The adverse outcomes associated with GCs, including weight gain, appearance associated with Cushing syndrome, short stature, behavior changes, low bone density, bone fractures, and cataracts, negatively impact quality of life among individuals with DMD.<sup><xref rid="zoi211221r16" ref-type="bibr">16</xref></sup> Other GC-associated safety concerns include adrenal suppression, delayed puberty, insulin resistance, and further muscle damage.<sup><xref rid="zoi211221r17" ref-type="bibr">17</xref>,<xref rid="zoi211221r18" ref-type="bibr">18</xref></sup> The significant adverse growth and development outcomes associated with GCs hinder their routine administration among children aged younger than 2 years, even though earlier administration may be associated with better overall functional outcomes.<sup><xref rid="zoi211221r19" ref-type="bibr">19</xref>,<xref rid="zoi211221r20" ref-type="bibr">20</xref>,<xref rid="zoi211221r21" ref-type="bibr">21</xref></sup> A current goal of DMD research is to find a variant-independent treatment that matches or exceeds the efficacy of GC with a significantly better adverse outcome profile.</p>
              <p>Vamorolone is a first-in-class steroidal anti-inflammatory drug that differs from conventional GCs in lacking an 11β hydroxy-carbonyl group.<sup><xref rid="zoi211221r22" ref-type="bibr">22</xref></sup> This difference removes a contact site with the target glucocorticoid receptor and significantly alters structure and activity associations.<sup><xref rid="zoi211221r23" ref-type="bibr">23</xref></sup> Additionally, unlike GC, vamorolone is not a substrate for 11β-hydroxysteroid dehydrogenase regulatory enzymes and is a potent antagonist of the mineralocorticoid receptor.<sup><xref rid="zoi211221r24" ref-type="bibr">24</xref></sup></p>
              <p>A Phase IIa 2-week (VBP15-002, NCT02760264) multiple ascending dose study<sup><xref rid="zoi211221r25" ref-type="bibr">25</xref></sup> of vamorolone (developmental code name, VBP) among boys with DMD who were GC naive and aged 4 years to less than 7 years was completed in 2017. Based on clinical safety and pharmacodynamic biomarker analysis, vamorolone showed dose-dependent anti-inflammatory activity. Findings from a Phase IIa 24-week (VBP15-003, NCT02760277) open-label dose-finding study<sup><xref rid="zoi211221r26" ref-type="bibr">26</xref></sup> suggested efficacy of vamorolone treatment at 2.0 and 6.0 mg/kg/d based on motor outcomes. Interim analysis at 18 months of the vamorolone open-label extension study (VBP15-LTE, NCT03038399)<sup><xref rid="zoi211221r27" ref-type="bibr">27</xref></sup> found ongoing improvement in motor function and a favorable safety profile. Here, we report on the long-term efficacy, safety, and tolerability of vamorolone among boys with DMD who completed the 6-month dose-finding and 24-month long-term extension trials, with a total of up to 30 months of vamorolone treatment.</p>
            </sec>
            <sec id="H1-2-ZOI211221">
              <title>Methods</title>
              <p>This nonrandomized clinical study and all studies contributing patients were approved by ethics committees or institutional review boards as required by the participating international academic clinical recruitment sites. Written informed consent was obtained from parents or legal guardians, and assent was obtained from children recruited into each described trial. This report follows the Transparent Reporting of Evaluations With Nonrandomized Designs (<ext-link xlink:href="https://www.cdc.gov/trendstatement/" ext-link-type="uri">TREND</ext-link>) reporting guideline for nonrandomized studies.</p>
              <p>The Cooperative International Neuromuscular Research Group (CINRG) conducted 3 consecutive multicenter open-label vamorolone clinical trials.<sup><xref rid="zoi211221r25" ref-type="bibr">25</xref>,<xref rid="zoi211221r26" ref-type="bibr">26</xref></sup> Participants were recruited from 11 participating centers in the United States, Canada, United Kingdom, Sweden, Israel, and Australia (<xref rid="zoi211221f1" ref-type="fig">Figure 1</xref>). The 2-week multiple-ascending-dose study<sup><xref rid="zoi211221r25" ref-type="bibr">25</xref></sup> enrolled 48 boys (ages 4 to &lt;7 years) with DMD who were GC-naive from June 2016 to October 2017. All participants completed the initial study and were enrolled in a 24-week dose-finding trial<sup><xref rid="zoi211221r26" ref-type="bibr">26</xref></sup>; 2 participants subsequently withdrew for reasons unrelated to the study drug. The remaining 46 participants (ages 4.5-7.5 years) who completed the 6-month dose-finding study were eligible to enroll in a 24-month long-term extension (LTE) study, which started in February 2017 and was completed in April 2020.</p>
              <fig position="float" id="zoi211221f1" fig-type="figure">
                <label>Figure 1. </label>
                <caption>
                  <title>Flowchart of Vamorolone Long-term Extension (LTE) Study</title>
                  <p>VBP indicates vamorolone.</p>
                  <p><sup>a</sup>Treating physicians were permitted to up-titrate or down-titrate dose according to clinical judgement. There were 3 participants who ended the study at an intermediate dose of 4.0 mg/kg/d.</p>
                </caption>
                <graphic xlink:href="jamanetwopen-e2144178-g001" position="float"/>
              </fig>
              <sec id="H2-1-ZOI211221">
                <title>Study Design</title>
                <p>Throughout the studies, vamorolone was provided as a 4% flavored oral suspension taken daily at breakfast with a 240-mL glass of whole milk (approximately 8 g of fat) or equivalent high-fat food portion. Study participants were initially assigned to receive vamorolone at 1 of 4 dose levels (ie, 0.25, 0.75, 2.0, or 6.0 mg/kg/d) (eFigure 1 in <xref rid="note-ZOI211221-1-s" ref-type="supplementary-material">Supplement 1</xref>) and remained at the same dose level in the 2-week multiple ascending dose and 24-week dose-finding trials. The last visit of the 24-week dose-finding trial coincided with the baseline visit of the 24-month LTE trial. Multiple dose escalations to the highest dose (ie, 6.0 mg/kg/d) were permitted in the LTE protocol (<xref rid="note-ZOI211221-1-s" ref-type="supplementary-material">Supplement 2</xref>); de-escalations were also allowed in case of intolerability, at the discretion of investigators. Given the variable timing of dose escalations, prespecified analyses of drug-associated efficacy focused on 23 participants who were initially assigned and maintained on a 2.0 mg/kg/d or greater dose of vamorolone (ie, 2 mg/kg/d and 6 mg/kg/d dose groups, hereafter <italic>higher-dose</italic> groups) for up to 30 months.</p>
                <p>Additionally, participants from the CINRG Duchenne Natural History Study (DNHS) treated with GC were selected to serve as a historical control group for timed function tests and anthropometric measurements. The DNHS (NCT00468832) included 440 participants with DMD, with data collected from December 2005 to November 2016.<sup><xref rid="zoi211221r28" ref-type="bibr">28</xref>,<xref rid="zoi211221r29" ref-type="bibr">29</xref>,<xref rid="zoi211221r30" ref-type="bibr">30</xref></sup> Participants in DNHS were first eligible for inclusion in the control group after they had experienced 6 months of continuous GC exposure, with similar ages (ie, 4.5-7.5 years) as participants in the LTE study who had 6 months of vamorolone exposure at baseline after completing the dose-finding trial. For statistical matching between participants receiving higher-dose vamorolone and those in the DNHS, prespecified criteria (eAppendix 1 in <xref rid="note-ZOI211221-1-s" ref-type="supplementary-material">Supplement 1</xref>) were defined for coarsened exact matching (CEM).<sup><xref rid="zoi211221r31" ref-type="bibr">31</xref>,<xref rid="zoi211221r32" ref-type="bibr">32</xref></sup></p>
                <p>In addition, participants from the NorthStar United Kingdom (NSUK) Network were selected for inclusion in a second historical control group to allow for comparison of NorthStar Ambulatory Assessment (NSAA) scores, given that NSAA was not assessed for most participants in DNHS. Participants in NSUK<sup><xref rid="zoi211221r33" ref-type="bibr">33</xref></sup> included in this comparison were recruited from August 2005 to October 2019. Like participants from the DNHS, they were started on GC (any type or dose) for 6 months before the comparison baseline visit, with similar ages (4.5-7.5 years) at baseline compared with participants in the LTE, and were continuously maintained on GC (eAppendix 2 in <xref rid="note-ZOI211221-1-s" ref-type="supplementary-material">Supplement 1</xref>).</p>
              </sec>
              <sec id="H2-2-ZOI211221">
                <title>Measurements</title>
                <p>Study visits took place quarterly and included clinical and laboratory assessments with adverse event reporting. Standing height and weight were assessed at each study visit; height percentile, body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) and BMI <italic>z</italic> score were calculated centrally.<sup><xref rid="zoi211221r34" ref-type="bibr">34</xref></sup> Clinical efficacy evaluations were performed at baseline (ie, multiple ascending dose entry), 6 months (ie, LTE baseline), 18 months (ie, LTE month 12), and 30 months (ie, LTE month 24) of treatment with vamorolone. Assessment of efficacy included timed function tests (ie, time to stand from supine [TTSTAND], time to run or walk 10 m [TTRW], time to climb 4 stairs [TTCLIMB]),<sup><xref rid="zoi211221r35" ref-type="bibr">35</xref></sup> distance covered in 6-minute walk test (6MWT),<sup><xref rid="zoi211221r36" ref-type="bibr">36</xref></sup> NSAA score (total NSAA score is made up of the sum of scores on 17 ordinal tests, scored as 0, 1, or 2, with a 2 indicating normal activity with no obvious modification)<sup><xref rid="zoi211221r37" ref-type="bibr">37</xref></sup> and quantitative muscle testing (QMT) using the CINRG Quantitative Measurement System (measurements in pounds done unilaterally using the dominant side, if known, for each muscle group [ie, knee extension, knee flexion, elbow extension, and elbow flexion]).<sup><xref rid="zoi211221r38" ref-type="bibr">38</xref></sup> TTSTAND change from the multiple ascending dose study baseline to LTE month 24 was the primary efficacy end point. For TTSTAND, TTRW, and TTCLIMB, results in seconds were converted to velocities (ie, rises per second for TTSTAND, meters per second for TTRW, and tasks per second for TTCLIMB); participants unable to perform tests owing to disease progression had a velocity score imputed as 0.<sup><xref rid="zoi211221r25" ref-type="bibr">25</xref>,<xref rid="zoi211221r26" ref-type="bibr">26</xref></sup> Clinical evaluators were trained according to operating procedures that were standardized in the NSUK Network<sup><xref rid="zoi211221r33" ref-type="bibr">33</xref></sup> and vamorolone and DNHS participating centers.<sup><xref rid="zoi211221r39" ref-type="bibr">39</xref></sup></p>
                <p>Patient-reported outcomes and health-related quality of life were assessed by the Pediatric Outcomes Data Collection Instrument (PODCI)<sup><xref rid="zoi211221r40" ref-type="bibr">40</xref></sup> as an exploratory efficacy end point. The PODCI standardized Upper Extremity and Physical Function score is calculated using at least 4 items with valid nonmissing responses, with a possible range of 0 to 100. The standardized Transfer and Basic Mobility score is calculated using at least 7 items with valid nonmissing response, with a possible range of 0 to 100. Safety measurements included physical exam with weight and height, BMI, clinical laboratory tests, 12-lead electrocardiogram, bone age, lateral thoracolumbar spine x-ray, and adverse event (AE) reporting. All AEs were coded using the <italic>Medical Dictionary for Regulatory Activities</italic> (<italic>MedDRA</italic>, versions 19.0, 20.1, 21.0, and 21.1) system for reporting. Intensity of AEs was graded using the Common Terminology Criteria for Adverse Events version 4.03.</p>
              </sec>
              <sec id="H2-3-ZOI211221">
                <title>Statistical Analysis</title>
                <p>A statistical analysis plan prespecified the longitudinal within-study (based on paired <italic>t</italic> test) analyses of motor outcomes, biomarkers, and safety analyses (<xref rid="note-ZOI211221-1-s" ref-type="supplementary-material">Supplement 2</xref>). Summaries for TTSTAND, TTRW, TTCLIMB, 6MWT, NSAA, and QMT included descriptive statistics on observed values and changes from baseline values at each time.</p>
                <p>Comparison of participants in the LTE study receiving higher doses with the historical control group consisting of participants from DNHS receiving GC was based on longitudinal outcome data using a mixed-effect model with repeated measures (MMRM). Owing to NSUK participant-level data sharing restrictions, NSAA data were analyzed separately by NSUK researchers and summaries of change were compared with the higher-dose LTE cohort using independent <italic>t</italic> tests and a relative risk analysis of NSAA scores.<sup><xref rid="zoi211221r41" ref-type="bibr">41</xref></sup> Nonparametric maximum likelihood estimation (NPMLE) was used to estimate the observed survival curve (median time to event and bootstrapped CIs) for the first TTSTAND milestone of 10 or more seconds to assess the risk associated with future loss of ambulation for each cohort.<sup><xref rid="zoi211221r30" ref-type="bibr">30</xref></sup></p>
                <p>For the post hoc delayed-start analysis, 23 participants initially assigned to the vamorolone low-dose groups (ie, 0.25 and 0.75 mg/kg/d) during the first 6 months of the dose-finding study were considered to have delayed starts. Outcomes for these participants were compared with outcomes among 23 participants who were initially assigned to and retained on higher-dose vamorolone (ie, 2.0 and 6.0 mg/kg/d) throughout their follow-up and were considered to have early starts. Estimates and standard errors were calculated using MMRM.</p>
                <p>Data manipulation, tabulation of descriptive statistics, and graphical representations were performed primarily using statistical software SAS version 9.4 or higher (SAS Institute) and R version 4.1.0 (R Project for Statistical Computing). The following R packages were used: interval,<sup><xref rid="zoi211221r42" ref-type="bibr">42</xref></sup> lme4,<sup><xref rid="zoi211221r43" ref-type="bibr">43</xref></sup> lmerTest,<sup><xref rid="zoi211221r44" ref-type="bibr">44</xref></sup> sjPlot,<sup><xref rid="zoi211221r45" ref-type="bibr">45</xref></sup> visreg,<sup><xref rid="zoi211221r46" ref-type="bibr">46</xref></sup> and vistime.<sup><xref rid="zoi211221r47" ref-type="bibr">47</xref></sup> All statistical tests were 2-sided, and a resultant <italic>P</italic> value  ≤ .05 was considered statistically significant. No adjustments for multiplicity on inferential statistics were made as per the statistical analysis plan (<xref rid="note-ZOI211221-1-s" ref-type="supplementary-material">Supplement 2</xref>). Data were analyzed from July 2020 through November 2021. More details regarding statistical modeling, as well as real-world comparator populations (ie, historical control groups with different GCs [prednisone or deflazacort], and regimen [daily or intermittent]) are provided in eAppendix 3 in <xref rid="note-ZOI211221-1-s" ref-type="supplementary-material">Supplement 1</xref>.</p>
              </sec>
            </sec>
            <sec id="H1-3-ZOI211221">
              <title>Results</title>
              <p>Among 46 boys with DMD who completed the dose-finding study, 41 participants (89.1%; baseline mean [SD] age, 5.33 [0.96] years) completed the 2-year LTE treatment period; 5 participants withdrew for reasons unrelated to the study drug (<xref rid="zoi211221f1" ref-type="fig">Figure 1</xref>). At the LTE month 24 visit, 11 participants, 3 participants, and 27 participants were being treated at 2.0 mg/kg/d, 4.0 mg/kg/d, and 6.0 mg/kg/d, respectively (eFigure 1 in <xref rid="note-ZOI211221-1-s" ref-type="supplementary-material">Supplement 1</xref>). Analysis of treatment efficacy focused on 23 participants receiving higher-dose vamorolone who were initially assigned and maintained on 2.0 mg/kg/d or more for up to 30 months during the dose-finding study (6 months) and LTE study (24 months). Demographic and clinical characteristics of participants in the LTE study receiving higher doses are summarized in <xref rid="zoi211221t1" ref-type="table">Table 1</xref>. The mean (SD) baseline age was 5.83 (0.88) years in the higher-dose LTE group. In the higher-dose LTE group, 3 participants (13.0%) withdrew before the LTE month 24 study visit. The subsets of participants receiving higher doses who completed all planned outcomes are summarized in eAppendix 3 in <xref rid="note-ZOI211221-1-s" ref-type="supplementary-material">Supplement 1</xref>.</p>
              <table-wrap position="float" id="zoi211221t1">
                <label>Table 1. </label>
                <caption>
                  <title>Participant Demographic and Baseline Characteristics for External Comparisons<xref rid="zoi211221t1n1" ref-type="table-fn"><sup>a</sup></xref></title>
                </caption>
                <table frame="hsides" rules="groups">
                  <col width="38.48%" span="1"/>
                  <col width="19.85%" span="1"/>
                  <col width="18.17%" span="1"/>
                  <col width="23.5%" span="1"/>
                  <thead>
                    <tr>
                      <th rowspan="2" valign="top" align="left" scope="col" colspan="1">Characteristic</th>
                      <th colspan="3" valign="top" align="left" scope="colgroup" rowspan="1">Participants</th>
                    </tr>
                    <tr>
                      <th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">Higher-dose VBP15-LTE (N = 23)<xref rid="zoi211221t1n2" ref-type="table-fn"><sup>b</sup></xref></th>
                      <th valign="top" align="left" scope="col" rowspan="1" colspan="1">GC in CINRG DNHS (N = 75)</th>
                      <th valign="top" align="left" scope="col" rowspan="1" colspan="1">GC in NorthStar UK Network (N = 110)<xref rid="zoi211221t1n3" ref-type="table-fn"><sup>c</sup></xref></th>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Age at baseline comparison visit, y</td>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Mean (SD)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">5.83 (0.88)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">6.08 (0.81)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">6.00 (0.77)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Median (range)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">5.65 (4.60-7.29)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">5.97 (4.50-7.48)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">5.94 (NA)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Steroid exposure at baseline comparison visit, mean (SD), d</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">200.57 (7.54)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">227.73 (61.91)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">264.84 (57.39)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Duration of follow up from baseline visit, mean (SD), y<xref rid="zoi211221t1n4" ref-type="table-fn"><sup>d</sup></xref></td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1.85 (0.46)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1.36 (0.49)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Participants with &gt;18 mo follow-up after initial 6 mo of steroid exposure, No. (%)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">21 (91.3)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">30 (40.0)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Weight (kg), No.</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">23</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">73</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Mean (SD)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">21.98 (3.78)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">20.35 (3.55)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Median (range)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">22.50 (16.30-32.60)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">20.10 (14.80-32.60)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Height (cm), No.</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">22</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">73</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Mean (SD)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">111.80 (6.94)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">109.86 (6.86)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Median (range)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">113.05 (100.60-123.00)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">110.00 (96.10-126.30)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Body Mass Index, No.</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">22</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">72</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Mean (SD)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">17.68 (1.23)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">16.68 (1.55)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Median (range)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">17.65 (15.90-21.50)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">16.56 (12.19-20.44)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot>
                  <p>Abbreviations: CINRG, Cooperative International Neuromuscular Research Group; DNHS, Duchenne Natural History Study; GC, glucocorticoid; LTE, long-term extension; NA, not applicable; VBP, vamorolone.</p>
                  <fn id="zoi211221t1n1">
                    <label>
                      <sup>a</sup>
                    </label>
                    <p>Based on baseline comparator visit, which corresponds to approximately 6 months of steroid exposure for participants in the NorthStar UK Network and CINRG DNHS.</p>
                  </fn>
                  <fn id="zoi211221t1n2">
                    <label>
                      <sup>b</sup>
                    </label>
                    <p>The higher-dose cohort refers to participants assigned to vamorolone 2.0 and 6.0 mg/kg/d from initial dose-finding (VBP15-002/-003) studies and maintained at 2.0 mg/kg/d or more from long-term extension (VBP15-LTE) baseline.</p>
                  </fn>
                  <fn id="zoi211221t1n3">
                    <label>
                      <sup>c</sup>
                    </label>
                    <p>Owing to NorthStar UK Network participant-level data-sharing restrictions, limited summary information was available.</p>
                  </fn>
                  <fn id="zoi211221t1n4">
                    <label>
                      <sup>d</sup>
                    </label>
                    <p>Reported for time to stand velocity.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <sec id="H2-4-ZOI211221">
                <title>Changes in Functional Outcomes Among Participants in LTE With Higher Doses</title>
                <p>Among 23 participants started on higher-dose vamorolone, 21 individuals were treated throughout the dose-finding and LTE studies and had available data at 30 months (3 individuals dropped out, but for 1 individual, terminal visit data was available close to 30 months and counted as such based on procedures). In these individuals, there was a decrease from baseline to 30 months in mean (SD) TTSTAND velocity (0.206 [0.070] rises/s vs 0.189 [0.124] rises/s), which was not a statistically significant change (−0.011 rises/s; 95% CI, −0.068 to 0.046 rises/s). Similarly, there were no significant changes from baseline to 30 months in TTCLIMB velocity score among 18 participants with TTCLIMB data (0.035 tasks/s; 95% CI, −0.051 to 0.121 tasks/s), TTRW velocity score among 18 participants with TTRW data (0.061 m/s; 95% CI, −0.272 to 0.394 m/s), 6MWT total distance among 15 participants with 6MWT data (32.0 m; 95% CI, −18.95 to 82.95 m), and total NSAA score among 18 participants with NSAA data (1.6; 95% CI, −2.92 to 6.14). There was no statistically significant change in PODCI transfer and basic mobility scores from baseline to 30 months (eTable 2 in <xref rid="note-ZOI211221-1-s" ref-type="supplementary-material">Supplement 1</xref>), and interpretation of QMT was limited by few observations after 30 months (eTable 3 in <xref rid="note-ZOI211221-1-s" ref-type="supplementary-material">Supplement 1</xref>).</p>
                <p>In a delayed start analysis, participants initiated on higher-dose vamorolone (ie, those with early starts) had better clinical outcomes at 6 months compared with those initially treated with low doses (ie, those with delayed starts). At 6, 18, and 30 months, the means of all 5 motor outcome measures were increased for participants with early starts compared with those with delayed starts, although not all differences were statistically significant. At 30 months, no means were statistically significantly different (<xref rid="zoi211221f2" ref-type="fig">Figure 2</xref>).</p>
                <fig position="float" id="zoi211221f2" fig-type="figure">
                  <label>Figure 2. </label>
                  <caption>
                    <title>Efficacy of Vamorolone in Motor Function Assessments by High vs Low Starting Dose</title>
                    <p>6MWT indicates 6-minute walk test; high, a starting dose of 2.0 mg/kg/d or greater; low, a starting dose of less than 2.0 mg/kg/d; points, means; whiskers, standard error of the mean. Mean estimated differences between participants treated at higher dose and low dose, as well as <italic>P</italic> values, are provided at 6 months (ie, prior to LTE) and 30 months (ie, at conclusion of LTE).</p>
                  </caption>
                  <graphic xlink:href="jamanetwopen-e2144178-g002" position="float"/>
                </fig>
              </sec>
              <sec id="H2-5-ZOI211221">
                <title>Efficacy of Higher-Dose Vamorolone Compared With GC Treatment in Historical Control Groups</title>
                <p>The mean (SD) baseline age was 6.08 (0.81) years among 75 participants in the DNHS control group and 6.00 (0.77) years among 110 participants in the NorthStar UK Network control group. An increased proportion of participants in the higher-dose LTE group had more than 18 months of follow-up after the initial 6 months of steroid exposure compared with participants in the DNHS control group (21 participants [91.3%] vs 30 participants [40.0%]). As noted previously, 75 participants from DNHS and 23 participants from the LTE study receiving higher doses were criteria-matched and subjected to CEM, yielding a smaller subset of matched comparator group (including 29 participants from DNHS and 20 participants from the LTE study). However, participants from DNHS who were CEM-matched had limited follow-up data, and the baseline characteristics of these participants with approximately 2 years of long-term follow-up (which would inform longitudinal analysis) were dissimilar to those from participants in the LTE study who were CEM-matched, resulting in unsuccessful CEM for longitudinal comparison (eTable 1 in <xref rid="note-ZOI211221-1-s" ref-type="supplementary-material">Supplement 1</xref>). Hence, we conducted a prespecified sensitivity analysis among 75 participants from DNHS and 23 participants from LTE; we present these comparisons in <xref rid="zoi211221t1" ref-type="table">Table 1</xref> and <xref rid="zoi211221t2" ref-type="table">Table 2</xref>.</p>
                <table-wrap position="float" id="zoi211221t2">
                  <label>Table 2. </label>
                  <caption>
                    <title>Comparison of Study Primary Efficacy and Safety Outcome Measures</title>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col width="30.2%" span="1"/>
                    <col width="14.44%" span="1"/>
                    <col width="17.38%" span="1"/>
                    <col width="17.38%" span="1"/>
                    <col width="20.6%" span="1"/>
                    <thead>
                      <tr>
                        <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Outcome</th>
                        <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Unique participants (longitudinal samples used), No. (No.)</th>
                        <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Baseline mean (SD)<xref rid="zoi211221t2n1" ref-type="table-fn"><sup>a</sup></xref></th>
                        <th valign="top" align="left" scope="col" rowspan="1" colspan="1">End of follow up mean (SD)<xref rid="zoi211221t2n2" ref-type="table-fn"><sup>b</sup></xref></th>
                        <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Statistical model or test <italic>P</italic> value (2-sided 95% CI)</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Efficacy</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">TTSTAND velocity, rises/s</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Higher-dose vamorolone LTE<xref rid="zoi211221t2n3" ref-type="table-fn"><sup>c</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1">23 (66)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.25 (0.10)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.20 (0.13)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">vs DNHS (MMRM)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> GC in DNHS</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">75 (313)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.25 (0.10)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.25 (0.13)</td>
                        <td rowspan="2" valign="top" align="left" colspan="1">Quadratic comparison<xref rid="zoi211221t2n4" ref-type="table-fn"><sup>d</sup></xref>: &gt;.99 (−0.30 to 0.30);<break/>linear comparison: <italic>.</italic>10 (−0.66 to 0.05)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> With ≥1.5 y follow-up)<xref rid="zoi211221t2n5" ref-type="table-fn"><sup>e</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1">30 (153)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.24 (0.09)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.24 (0.12)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">TTCLIMB velocity, tasks/s</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Higher-dose vamorolone LTE<xref rid="zoi211221t2n3" ref-type="table-fn"><sup>c</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1">23 (63)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.31 (0.13)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.32 (0.19)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">vs DNHS (MMRM)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> GC in DNHS</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">75 (311)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.32 (0.14)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.33 (0.18)</td>
                        <td rowspan="2" valign="top" align="left" colspan="1">Quadratic comparison: &gt;.99 (–0.36 to 0.36)<break/>linear comparison:  <italic>.</italic>93 (−0.41 to 0.44)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> With ≥1.5 y follow-up)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">30 (153)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.31 (0.13)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.32 (0.16)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">TTRW velocity, meters/s</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Higher-dose vamorolone LTE<xref rid="zoi211221t2n3" ref-type="table-fn"><sup>c</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1">23 (63)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1.90 (0.34)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1.87 (0.63)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">vs DNHS (MMRM)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> GC in DNHS</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">75 (317)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1.91 (0.52)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1.89 (0.71)</td>
                        <td rowspan="2" valign="top" align="left" colspan="1">Quadratic comparison: <italic>.</italic>90 (−1.24 to 1.41)<break/>Linear comparison: <italic>.</italic>94 (−1.57 to 1.46)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> With ≥1.5 years follow-up)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">30 (153)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1.85 (0.37)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1.85 (0.64)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">6MWT, m walked</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Higher-dose vamorolone LTE<xref rid="zoi211221t2n3" ref-type="table-fn"><sup>c</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1">20 (37)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">377.9 (64.77)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">369.9 (77.81)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">Paired sample (within group) <italic>t</italic> test: <italic>.</italic>20 (−18.95 to 82.95)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">NSAA score<xref rid="zoi211221t2n6" ref-type="table-fn"><sup>f</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Higher-dose vamorolone LTE<xref rid="zoi211221t2n3" ref-type="table-fn"><sup>c</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1">23 (41)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">22.3 (4.72)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">21.78 (7.86)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">vs NorthStar UK cohort (independent <italic>t</italic> test on change over 2 y)<xref rid="zoi211221t2n6" ref-type="table-fn"><sup>f</sup></xref></td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> GC in NSUK Network</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">110 (159)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">26.63 (5.65)<xref rid="zoi211221t2n7" ref-type="table-fn"><sup>g</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1">26.24 (7.2)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"><italic>.</italic>92 (−4.48 to 4.04)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Height percentile</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Higher-dose vamorolone LTE<xref rid="zoi211221t2n3" ref-type="table-fn"><sup>c</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1">23 (65)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">32.26 (26.87)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">37.03 (31.14)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">vs DNHS (MMRM)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> GC in DNHS</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">75 (312)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">19.88 (21.70)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">13.42 (18.62)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">8.94 × 10<sup>−7</sup> (0.23 to 0.52)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">BMI <italic>z</italic> score</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Higher-dose vamorolone LTE<xref rid="zoi211221t2n3" ref-type="table-fn"><sup>c</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1">23 (65)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1.28 (0.51)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1.52 (0.66)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">vs DNHS (MMRM)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> GC in DNHS</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">75 (309)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.65 (1.03)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.79 (1.11)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"><italic>.</italic>58 (−0.01 to 0.01)</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <p>Abbreviations: DNHS, Duchenne Natural History Study; GC, glucocorticoid; LTE, long-term extension; MMRM, mixed-effect model with repeated measures; NSAA, NorthStar Ambulatory Assessment; NSUK, NorthStar United Kingdom; TTCLIMB, time to climb 4 stairs; TTRW, time to run or walk 10 m; TTSTAND, time to stand from supine position; 6MWT, 6-minute walk test distance.</p>
                    <fn id="zoi211221t2n1">
                      <label>
                        <sup>a</sup>
                      </label>
                      <p>Baseline values after approximately 6 months of continual treatment with vamorolone or GC.</p>
                    </fn>
                    <fn id="zoi211221t2n2">
                      <label>
                        <sup>b</sup>
                      </label>
                      <p>Last visit of participants is used. One participant in vamorolone LTE had 1 measurement and was included in baseline comparator and end of follow-up summaries.</p>
                    </fn>
                    <fn id="zoi211221t2n3">
                      <label>
                        <sup>c</sup>
                      </label>
                      <p>Participants assigned to higher-dose vamorolone (ie, 2.0 and 6.0 mg/kg/d) at start of study and maintained at 2.0 mg/kg/d or more at follow up.</p>
                    </fn>
                    <fn id="zoi211221t2n4">
                      <label>
                        <sup>d</sup>
                      </label>
                      <p>The multivariable model included a quadratic term in addition to model trajectories (ie, Duchenne muscular dystrophy natural history during the age range of interest includes periods of improvement followed by stability and deterioration); <italic>P</italic> values are provided for comparisons between comparator cohorts.</p>
                    </fn>
                    <fn id="zoi211221t2n5">
                      <label>
                        <sup>e</sup>
                      </label>
                      <p>DNHS is a natural history study with different participants followed up for different durations in the age range of comparison. Summary characteristics are also provided for participants in DNHS with 1.5 years or more of follow-up in the age range of interest.</p>
                    </fn>
                    <fn id="zoi211221t2n6">
                      <label>
                        <sup>f</sup>
                      </label>
                      <p>Owing to NorthStar UK Network participant-level data sharing restrictions, NSAA data was analyzed separately by UK Network researchers and summaries were shared for comparison with the vamorolone LTE cohort. NSAA data had a possible range from 0 to 34.</p>
                    </fn>
                    <fn id="zoi211221t2n7">
                      <label>
                        <sup>g</sup>
                      </label>
                      <p>Owing to the use of independent <italic>t</italic> test for change in NSAA over 2 years, the baseline mean is provided for 49 participants with 2 years of follow-up.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <p>In longitudinal comparison of mean TTSTAND, TTRW, and TTCLIMB velocity from baseline to end of follow-up, the LTE group and DNHS group were not significantly different (<xref rid="zoi211221t2" ref-type="table">Table 2</xref>, <xref rid="zoi211221f3" ref-type="fig">Figure 3</xref>; eFigure 2 in <xref rid="note-ZOI211221-1-s" ref-type="supplementary-material">Supplement 2</xref>). Mean TTSTAND velocity trajectories were not significantly different (estimates of difference from interaction of orthogonal polynomial terms with cohort: quadratic term coefficient estimate, 0.001; 95% CI, −0.30 to 0.30; <italic>P</italic> &gt; .99; linear term coefficient estimate, −0.30; 95% CI, −0.66 to 0.05; <italic>P</italic> = .10). There was no significant difference in the NPMLE estimate of time to reach a TTSTAND milestone of 10 seconds or more between 22 participants in the higher-dose LTE not beyond 10 seconds at baseline (median age, &gt;9.31 years; 95% CI, 7.51 to ∞ years) and 74 participants in the DNHS group not beyond 10 seconds at baseline (median age, &gt;9.31 years; 95% CI, 8.29 to ∞ years) (asymptotic log-rank 2-sample test <italic>P</italic> = .74).</p>
                <fig position="float" id="zoi211221f3" fig-type="figure">
                  <label>Figure 3. </label>
                  <caption>
                    <title>Outcome Comparisons of Vamorolone Long-term Extension (LTE) and Duchenne Natural History (DNHS) Study Cohorts</title>
                    <p>BMI indicates body mass index. Trajectories based on model estimates, along with 95% CIs, are plotted for an individual with fixed baseline values.</p>
                  </caption>
                  <graphic xlink:href="jamanetwopen-e2144178-g003" position="float"/>
                </fig>
                <p>Change in mean total NSAA score for 18 participants receiving higher-dose vamorolone with NSAA data (−0.61; 95% CI, −4.65 to 3.43) vs 49 participants in NSUK receiving GC with NSAA data (–0.39; 95% CI, −1.91 to 1.13) at 2-years of follow-up was not statistically significantly different (0.22 units; 95% CI, −4.48 to 4.04; <italic>P</italic> = .92) (<xref rid="zoi211221t2" ref-type="table">Table 2</xref>). Additionally, body mass index <italic>z</italic> score change (0.002 SD/mo; 95% CI, −0.006 to 0.010; <italic>P</italic> = .58) was not significantly different between the higher-dose vamorolone group vs the DNHS group. The NPMLE estimate of time to reach a TTSTAND milestone of 10 seconds or more for 108 participants in NSUK who had not experienced this event by baseline (median age, 9.55 years; 95% CI, 8.87 to ∞ years) was similar to that for participants in DNHS and participants in the LTE study receiving higher doses. Additionally, a relative risk analysis of NSAA scores showed no significant difference in the risk of losing a motor function (ie, change from a function score of a 1 or 2 at baseline to a 0 at the end of follow-up) between participants in NSUK and participants in the LTE study receiving higher doses (139 of 1734 functions lost [8.0%] vs 26 of 335 functions lost [7.8%]; relative risk, 1.033 [95% CI, 0.691 to 1.544]).</p>
              </sec>
              <sec id="H2-6-ZOI211221">
                <title>Safety Analysis of LTE Cohort</title>
                <p>During the 24-month LTE treatment period, all 46 participants experienced at least 1 treatment-emergent AE (eTable 4 in <xref rid="note-ZOI211221-1-s" ref-type="supplementary-material">Supplement 1</xref>). Among 41 participants receiving vamorolone at 6.0 mg/kg/d, 10 participants (24.4%) deescalated to 2.0 mg/kg/d owing to a treatment-emergent AE of weight gain. The AE abated among 6 participants after dose reduction. Among the 46 LTE participants, 6 participants (13.0%) were observed to have a total of 7 clinical fracture events according to local site AE reporting, including 1 participant with a vertebral fracture and a foot fracture on 2 separate occasions, 3 participants with an upper limb fracture, 1 participant with a vertebral compression fracture, and 1 participant with multiple vertebral fractures. There were 2 serious treatment-emergent AEs: moderate pneumonia in 1 participant and severe myoglobinuria, which occurred twice in 1 participant; 1 participant withdrew from the study owing to moderate muscle weakness. These treatment-emergent AEs were considered by the investigators to not be associated with the study drug.</p>
                <p>Mean changes in hematology, chemistry, liver function, lipid profile, urinalysis, and electrocardiogram parameters were minimal and clinically unremarkable. There was no significant difference in changes to mean BMI <italic>z</italic> scores between participants receiving higher-dose vamorolone and those from DNHS (<xref rid="zoi211221f3" ref-type="fig">Figure 3</xref>D). In comparison of participants receiving higher-dose vamorolone with participants from DNHS treated with GC, there was a statistically significant difference in change in mean height percentile change (0.37 percentile/mo; 95% CI, 0.23 to 0.52 percentile/mo), with no evidence of growth deceleration in the vamorolone group (<xref rid="zoi211221f3" ref-type="fig">Figure 3</xref>E; eFigure 3 in <xref rid="note-ZOI211221-1-s" ref-type="supplementary-material">Supplement 1</xref>). Among 41 participants in LTE who finished the 2-year LTE period, 39 participants (95.1%) had a hand and wrist x-ray at month 24; the mean bone age to chronologic age difference was −1.1 years (95% CI, −1.5 to −0.7 years). Results on serum biomarkers of safety including insulin resistance, adrenal suppression, and bone turnover will be presented in a separate report.</p>
              </sec>
            </sec>
            <sec id="H1-4-ZOI211221">
              <title>Discussion</title>
              <p>The results of this nonrandomized clinical trial extend the findings of previous reports on open-label vamorolone treatment among boys with DMD to a total treatment duration of 30 months.<sup><xref rid="zoi211221r25" ref-type="bibr">25</xref>,<xref rid="zoi211221r26" ref-type="bibr">26</xref>,<xref rid="zoi211221r27" ref-type="bibr">27</xref></sup> We found that vamorolone treatment was not associated with a change in TTSTAND velocity from baseline to 30 months among boys with DMD aged 4 to 7 years at enrollment. However, based on clinical and laboratory results, long-term vamorolone treatment at doses up to 6.0 mg/kg/d appeared to be safe and well-tolerated. While there was an overall decline after initial improvement in TTSTAND velocity observed among boys treated with vamorolone over 2 years, vamorolone showed similar treatment efficacy as GC in DMD,<sup><xref rid="zoi211221r48" ref-type="bibr">48</xref></sup> and the decline was slower compared with that of untreated patients.<sup><xref rid="zoi211221r26" ref-type="bibr">26</xref>,<xref rid="zoi211221r27" ref-type="bibr">27</xref></sup> Moreover, participants receiving higher doses (ie, ≥2 mg/kg/d) of vamorolone had persistent improvement in motor function as measured by TTCLIMB, TTRW, NSAA, and 6MWT distance over a 30-month treatment period.</p>
              <p>Vamorolone treatment was associated with fewer adverse outcomes compared with GC therapy. Continuous treatment with vamorolone for up to 30 months was not associated with linear growth deceleration, whereas growth delay is a well-recognized adverse outcome associated with traditional GC, which can be distressing to boys with DMD as they mature through adolescence.<sup><xref rid="zoi211221r49" ref-type="bibr">49</xref>,<xref rid="zoi211221r50" ref-type="bibr">50</xref>,<xref rid="zoi211221r51" ref-type="bibr">51</xref></sup> We observed that boys treated with vamorolone had minimal bone age delay relative to chronological age. In this setting of improved growth velocity with vamorolone, the slight bone age delay is anticipated to be favorable for these patients to attain increased adult height associated with greater residual growth potential. Although some participants receiving high-dose vamorolone had dose reduction to address undesired weight gain, the change in mean BMI <italic>z</italic> score was not significantly different between participants receiving vamorolone compared with participants in DNHS receiving GC.<sup><xref rid="zoi211221r27" ref-type="bibr">27</xref></sup> To date, pharmacodynamic biomarker data suggest that vamorolone is not associated with short-term detrimental bone outcomes.<sup><xref rid="zoi211221r25" ref-type="bibr">25</xref></sup> Additionally, vamorolone does not have the same association with insulin resistance as classic GC therapy; however, long-term vamorolone treatment may be associated with adrenal suppression.<sup><xref rid="zoi211221r27" ref-type="bibr">27</xref></sup></p>
              <sec id="H2-7-ZOI211221">
                <title>Limitations</title>
                <p>This study has several limitations. The open-label study design and use of prospectively collected real-world observational control data sets with different GCs (ie, prednisone or deflazacort), dose, and regimen (ie, daily or intermittent as per clinical practice<sup><xref rid="zoi211221r16" ref-type="bibr">16</xref>,<xref rid="zoi211221r52" ref-type="bibr">52</xref></sup>) require cautious interpretation of the study results. The comparator data sets included patients with DMD who had been on GC for a variable amount of time before the baseline comparator visits. There was also considerable attrition in the data of participants in comparator groups over time (eg, 91.3% of participants in LTE vs 40.0% of participants in DNHS had &gt;18 months of follow-up data for TTSTAND velocity). Despite strict subset enrollment criteria and adjustment for baseline characteristics, confounding is still possible. We could not look for association between height and motor function among patients treated with vamorolone and GC owing to the nonrandomized study design and small sample size; the risk of adrenal insufficiency will require additional studies.</p>
              </sec>
            </sec>
            <sec id="H1-5-ZOI211221">
              <title>Conclusions</title>
              <p>We found that vamorolone, a novel dissociative steroidal anti-inflammatory drug, was not associated with a change in TTSTAND velocity from baseline to 30 months among boys with DMD aged 4 to 7 at enrollment. However, vamorolone was associated with similar efficacy and maintenance of muscle function comparable to historical cohorts of patients with DMD treated with GC after treatment for 30 months. Vamorolone appeared to be well-tolerated, with fewer safety concerns that are typically seen with standard-of-care GC treatment for ambulatory patients with DMD. A randomized double-blind vamorolone study (VBP15-004; NCT03439670) is near completion; results from this study will provide class I evidence for vamorolone efficacy and safety.</p>
            </sec>
          </body>
          <back>
            <ref-list id="REF-ZOI211221">
              <title>References</title>
              <ref id="zoi211221r1">
                <label>1</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Mah</surname><given-names>JK</given-names></string-name>, <string-name><surname>Korngut</surname><given-names>L</given-names></string-name>, <string-name><surname>Dykeman</surname><given-names>J</given-names></string-name>, <string-name><surname>Day</surname><given-names>L</given-names></string-name>, <string-name><surname>Pringsheim</surname><given-names>T</given-names></string-name>, <string-name><surname>Jette</surname><given-names>N</given-names></string-name></person-group>. <article-title>A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy</article-title>. <source>Neuromuscul Disord</source>. <year>2014</year>;<volume>24</volume>(<issue>6</issue>):<fpage>482</fpage>-<lpage>491</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.nmd.2014.03.008</pub-id><?supplied-pmid 24780148?><pub-id pub-id-type="pmid">24780148</pub-id></mixed-citation>
              </ref>
              <ref id="zoi211221r2">
                <label>2</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Hoffman</surname><given-names>EP</given-names></string-name>, <string-name><surname>Brown</surname><given-names>RH</given-names><suffix>Jr</suffix></string-name>, <string-name><surname>Kunkel</surname><given-names>LM</given-names></string-name></person-group>. <article-title>Dystrophin: the protein product of the Duchenne muscular dystrophy locus</article-title>. <source>Cell</source>. <year>1987</year>;<volume>51</volume>(<issue>6</issue>):<fpage>919</fpage>-<lpage>928</lpage>. doi:<pub-id pub-id-type="doi">10.1016/0092-8674(87)90579-4</pub-id><?supplied-pmid 3319190?><pub-id pub-id-type="pmid">3319190</pub-id></mixed-citation>
              </ref>
              <ref id="zoi211221r3">
                <label>3</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Evans</surname><given-names>NP</given-names></string-name>, <string-name><surname>Misyak</surname><given-names>SA</given-names></string-name>, <string-name><surname>Robertson</surname><given-names>JL</given-names></string-name>, <string-name><surname>Bassaganya-Riera</surname><given-names>J</given-names></string-name>, <string-name><surname>Grange</surname><given-names>RW</given-names></string-name></person-group>. <article-title>Immune-mediated mechanisms potentially regulate the disease time-course of Duchenne muscular dystrophy and provide targets for therapeutic intervention</article-title>. <source>PM R</source>. <year>2009</year>;<volume>1</volume>(<issue>8</issue>):<fpage>755</fpage>-<lpage>768</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.pmrj.2009.04.010</pub-id><?supplied-pmid 19695529?><pub-id pub-id-type="pmid">19695529</pub-id></mixed-citation>
              </ref>
              <ref id="zoi211221r4">
                <label>4</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Chen</surname><given-names>YW</given-names></string-name>, <string-name><surname>Nagaraju</surname><given-names>K</given-names></string-name>, <string-name><surname>Bakay</surname><given-names>M</given-names></string-name>, <etal/></person-group>. <article-title>Early onset of inflammation and later involvement of TGFbeta in Duchenne muscular dystrophy</article-title>. <source>Neurology</source>. <year>2005</year>;<volume>65</volume>(<issue>6</issue>):<fpage>826</fpage>-<lpage>834</lpage>. doi:<pub-id pub-id-type="doi">10.1212/01.wnl.0000173836.09176.c4</pub-id><?supplied-pmid 16093456?><pub-id pub-id-type="pmid">16093456</pub-id></mixed-citation>
              </ref>
              <ref id="zoi211221r5">
                <label>5</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Rosenberg</surname><given-names>AS</given-names></string-name>, <string-name><surname>Puig</surname><given-names>M</given-names></string-name>, <string-name><surname>Nagaraju</surname><given-names>K</given-names></string-name>, <etal/></person-group>. <article-title>Immune-mediated pathology in Duchenne muscular dystrophy</article-title>. <source>Sci Transl Med</source>. <year>2015</year>;<volume>7</volume>(<issue>299</issue>):<elocation-id>299rv4</elocation-id>. doi:<pub-id pub-id-type="doi">10.1126/scitranslmed.aaa7322</pub-id><?supplied-pmid 26246170?><pub-id pub-id-type="pmid">26246170</pub-id></mixed-citation>
              </ref>
              <ref id="zoi211221r6">
                <label>6</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Kumar</surname><given-names>A</given-names></string-name>, <string-name><surname>Boriek</surname><given-names>AM</given-names></string-name></person-group>. <article-title>Mechanical stress activates the nuclear factor-kappaB pathway in skeletal muscle fibers: a possible role in Duchenne muscular dystrophy</article-title>. <source>FASEB J</source>. <year>2003</year>;<volume>17</volume>(<issue>3</issue>):<fpage>386</fpage>-<lpage>396</lpage>. doi:<pub-id pub-id-type="doi">10.1096/fj.02-0542com</pub-id><?supplied-pmid 12631578?><pub-id pub-id-type="pmid">12631578</pub-id></mixed-citation>
              </ref>
              <ref id="zoi211221r7">
                <label>7</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Acharyya</surname><given-names>S</given-names></string-name>, <string-name><surname>Villalta</surname><given-names>SA</given-names></string-name>, <string-name><surname>Bakkar</surname><given-names>N</given-names></string-name>, <etal/></person-group>. <article-title>Interplay of IKK/NF-kappaB signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy</article-title>. <source>J Clin Invest</source>. <year>2007</year>;<volume>117</volume>(<issue>4</issue>):<fpage>889</fpage>-<lpage>901</lpage>. doi:<pub-id pub-id-type="doi">10.1172/JCI30556</pub-id><?supplied-pmid 17380205?><pub-id pub-id-type="pmid">17380205</pub-id></mixed-citation>
              </ref>
              <ref id="zoi211221r8">
                <label>8</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Dogra</surname><given-names>C</given-names></string-name>, <string-name><surname>Changotra</surname><given-names>H</given-names></string-name>, <string-name><surname>Wergedal</surname><given-names>JE</given-names></string-name>, <string-name><surname>Kumar</surname><given-names>A</given-names></string-name></person-group>. <article-title>Regulation of phosphatidylinositol 3-kinase (PI3K)/Akt and nuclear factor-kappa B signaling pathways in dystrophin-deficient skeletal muscle in response to mechanical stretch</article-title>. <source>J Cell Physiol</source>. <year>2006</year>;<volume>208</volume>(<issue>3</issue>):<fpage>575</fpage>-<lpage>585</lpage>. doi:<pub-id pub-id-type="doi">10.1002/jcp.20696</pub-id><?supplied-pmid 16741926?><pub-id pub-id-type="pmid">16741926</pub-id></mixed-citation>
              </ref>
              <ref id="zoi211221r9">
                <label>9</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Pahl</surname><given-names>HL</given-names></string-name></person-group>. <article-title>Activators and target genes of Rel/NF-kappaB transcription factors</article-title>. <source>Oncogene</source>. <year>1999</year>;<volume>18</volume>(<issue>49</issue>):<fpage>6853</fpage>-<lpage>6866</lpage>. doi:<pub-id pub-id-type="doi">10.1038/sj.onc.1203239</pub-id><?supplied-pmid 10602461?><pub-id pub-id-type="pmid">10602461</pub-id></mixed-citation>
              </ref>
              <ref id="zoi211221r10">
                <label>10</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Spencer</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Montecino-Rodriguez</surname><given-names>E</given-names></string-name>, <string-name><surname>Dorshkind</surname><given-names>K</given-names></string-name>, <string-name><surname>Tidball</surname><given-names>JG</given-names></string-name></person-group>. <article-title>Helper (CD4(+)) and cytotoxic (CD8(+)) T cells promote the pathology of dystrophin-deficient muscle</article-title>. <source>Clin Immunol</source>. <year>2001</year>;<volume>98</volume>(<issue>2</issue>):<fpage>235</fpage>-<lpage>243</lpage>. doi:<pub-id pub-id-type="doi">10.1006/clim.2000.4966</pub-id><?supplied-pmid 11161980?><pub-id pub-id-type="pmid">11161980</pub-id></mixed-citation>
              </ref>
              <ref id="zoi211221r11">
                <label>11</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Spencer</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Tidball</surname><given-names>JG</given-names></string-name></person-group>. <article-title>Do immune cells promote the pathology of dystrophin-deficient myopathies?</article-title><source>Neuromuscul Disord</source>. <year>2001</year>;<volume>11</volume>(<issue>6-7</issue>):<fpage>556</fpage>-<lpage>564</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0960-8966(01)00198-5</pub-id><?supplied-pmid 11525885?><pub-id pub-id-type="pmid">11525885</pub-id></mixed-citation>
              </ref>
              <ref id="zoi211221r12">
                <label>12</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Griggs</surname><given-names>RC</given-names></string-name>, <string-name><surname>Moxley</surname><given-names>RT</given-names><suffix>III</suffix></string-name>, <string-name><surname>Mendell</surname><given-names>JR</given-names></string-name>, <etal/>; <collab>Clinical Investigation of Duchenne Dystrophy Group</collab></person-group>. <article-title>Prednisone in Duchenne dystrophy: a randomized, controlled trial defining the time course and dose response</article-title>. <source>Arch Neurol</source>. <year>1991</year>;<volume>48</volume>(<issue>4</issue>):<fpage>383</fpage>-<lpage>388</lpage>. doi:<pub-id pub-id-type="doi">10.1001/archneur.1991.00530160047012</pub-id><?supplied-pmid 2012511?><pub-id pub-id-type="pmid">2012511</pub-id></mixed-citation>
              </ref>
              <ref id="zoi211221r13">
                <label>13</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Mendell</surname><given-names>JR</given-names></string-name>, <string-name><surname>Moxley</surname><given-names>RT</given-names></string-name>, <string-name><surname>Griggs</surname><given-names>RC</given-names></string-name>, <etal/></person-group>. <article-title>Randomized, double-blind six-month trial of prednisone in Duchenne’s muscular dystrophy</article-title>. <source>N Engl J Med</source>. <year>1989</year>;<volume>320</volume>(<issue>24</issue>):<fpage>1592</fpage>-<lpage>1597</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJM198906153202405</pub-id><?supplied-pmid 2657428?><pub-id pub-id-type="pmid">2657428</pub-id></mixed-citation>
              </ref>
              <ref id="zoi211221r14">
                <label>14</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Malik</surname><given-names>V</given-names></string-name>, <string-name><surname>Rodino-Klapac</surname><given-names>LR</given-names></string-name>, <string-name><surname>Mendell</surname><given-names>JR</given-names></string-name></person-group>. <article-title>Emerging drugs for Duchenne muscular dystrophy</article-title>. <source>Expert Opin Emerg Drugs</source>. <year>2012</year>;<volume>17</volume>(<issue>2</issue>):<fpage>261</fpage>-<lpage>277</lpage>. doi:<pub-id pub-id-type="doi">10.1517/14728214.2012.691965</pub-id><?supplied-pmid 22632414?><pub-id pub-id-type="pmid">22632414</pub-id></mixed-citation>
              </ref>
              <ref id="zoi211221r15">
                <label>15</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Matthews</surname><given-names>E</given-names></string-name>, <string-name><surname>Brassington</surname><given-names>R</given-names></string-name>, <string-name><surname>Kuntzer</surname><given-names>T</given-names></string-name>, <string-name><surname>Jichi</surname><given-names>F</given-names></string-name>, <string-name><surname>Manzur</surname><given-names>AY</given-names></string-name></person-group>. <article-title>Corticosteroids for the treatment of Duchenne muscular dystrophy</article-title>. <source>Cochrane Database Syst Rev</source>. <year>2016</year>;<volume>2016</volume>(<issue>5</issue>):<elocation-id>CD003725</elocation-id>. doi:<pub-id pub-id-type="doi">10.1002/14651858.CD003725.pub4</pub-id><?supplied-pmid 27149418?><pub-id pub-id-type="pmid">27149418</pub-id></mixed-citation>
              </ref>
              <ref id="zoi211221r16">
                <label>16</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Bello</surname><given-names>L</given-names></string-name>, <string-name><surname>Gordish-Dressman</surname><given-names>H</given-names></string-name>, <string-name><surname>Morgenroth</surname><given-names>LP</given-names></string-name>, <etal/>; <collab>CINRG Investigators</collab></person-group>. <article-title>Prednisone/prednisolone and deflazacort regimens in the CINRG Duchenne Natural History Study</article-title>. <source>Neurology</source>. <year>2015</year>;<volume>85</volume>(<issue>12</issue>):<fpage>1048</fpage>-<lpage>1055</lpage>. doi:<pub-id pub-id-type="doi">10.1212/WNL.0000000000001950</pub-id><?supplied-pmid 26311750?><pub-id pub-id-type="pmid">26311750</pub-id></mixed-citation>
              </ref>
              <ref id="zoi211221r17">
                <label>17</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Kauh</surname><given-names>E</given-names></string-name>, <string-name><surname>Mixson</surname><given-names>L</given-names></string-name>, <string-name><surname>Malice</surname><given-names>MP</given-names></string-name>, <etal/></person-group>. <article-title>Prednisone affects inflammation, glucose tolerance, and bone turnover within hours of treatment in healthy individuals</article-title>. <source>Eur J Endocrinol</source>. <year>2012</year>;<volume>166</volume>(<issue>3</issue>):<fpage>459</fpage>-<lpage>467</lpage>. doi:<pub-id pub-id-type="doi">10.1530/EJE-11-0751</pub-id><?supplied-pmid 22180452?><pub-id pub-id-type="pmid">22180452</pub-id></mixed-citation>
              </ref>
              <ref id="zoi211221r18">
                <label>18</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Schakman</surname><given-names>O</given-names></string-name>, <string-name><surname>Kalista</surname><given-names>S</given-names></string-name>, <string-name><surname>Barbé</surname><given-names>C</given-names></string-name>, <string-name><surname>Loumaye</surname><given-names>A</given-names></string-name>, <string-name><surname>Thissen</surname><given-names>JP</given-names></string-name></person-group>. <article-title>Glucocorticoid-induced skeletal muscle atrophy</article-title>. <source>Int J Biochem Cell Biol</source>. <year>2013</year>;<volume>45</volume>(<issue>10</issue>):<fpage>2163</fpage>-<lpage>2172</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.biocel.2013.05.036</pub-id><?supplied-pmid 23806868?><pub-id pub-id-type="pmid">23806868</pub-id></mixed-citation>
              </ref>
              <ref id="zoi211221r19">
                <label>19</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Pane</surname><given-names>M</given-names></string-name>, <string-name><surname>Mazzone</surname><given-names>ES</given-names></string-name>, <string-name><surname>Sivo</surname><given-names>S</given-names></string-name>, <etal/></person-group>. <article-title>Long term natural history data in ambulant boys with Duchenne muscular dystrophy: 36-month changes</article-title>. <source>PLoS One</source>. <year>2014</year>;<volume>9</volume>(<issue>10</issue>):<elocation-id>e108205</elocation-id>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0108205</pub-id><?supplied-pmid 25271887?><pub-id pub-id-type="pmid">25271887</pub-id></mixed-citation>
              </ref>
              <ref id="zoi211221r20">
                <label>20</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Kim</surname><given-names>S</given-names></string-name>, <string-name><surname>Zhu</surname><given-names>Y</given-names></string-name>, <string-name><surname>Romitti</surname><given-names>PA</given-names></string-name>, <etal/>; <collab>MD STARnet</collab></person-group>. <article-title>Associations between timing of corticosteroid treatment initiation and clinical outcomes in Duchenne muscular dystrophy</article-title>. <source>Neuromuscul Disord</source>. <year>2017</year>;<volume>27</volume>(<issue>8</issue>):<fpage>730</fpage>-<lpage>737</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.nmd.2017.05.019</pub-id><?supplied-pmid 28645460?><pub-id pub-id-type="pmid">28645460</pub-id></mixed-citation>
              </ref>
              <ref id="zoi211221r21">
                <label>21</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Connolly</surname><given-names>AM</given-names></string-name>, <string-name><surname>Zaidman</surname><given-names>CM</given-names></string-name>, <string-name><surname>Golumbek</surname><given-names>PT</given-names></string-name>, <etal/>; <collab>MDA DMD Clinical Research Network</collab></person-group>. <article-title>Twice-weekly glucocorticosteroids in infants and young boys with Duchenne muscular dystrophy</article-title>. <source>Muscle Nerve</source>. <year>2019</year>;<volume>59</volume>(<issue>6</issue>):<fpage>650</fpage>-<lpage>657</lpage>. doi:<pub-id pub-id-type="doi">10.1002/mus.26441</pub-id><?supplied-pmid 30706490?><pub-id pub-id-type="pmid">30706490</pub-id></mixed-citation>
              </ref>
              <ref id="zoi211221r22">
                <label>22</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Reeves</surname><given-names>EKM</given-names></string-name>, <string-name><surname>Hoffman</surname><given-names>EP</given-names></string-name>, <string-name><surname>Nagaraju</surname><given-names>K</given-names></string-name>, <string-name><surname>Damsker</surname><given-names>JM</given-names></string-name>, <string-name><surname>McCall</surname><given-names>JM</given-names></string-name></person-group>. <article-title>VBP15: preclinical characterization of a novel anti-inflammatory delta 9,11 steroid</article-title>. <source>Bioorg Med Chem</source>. <year>2013</year>;<volume>21</volume>(<issue>8</issue>):<fpage>2241</fpage>-<lpage>2249</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.bmc.2013.02.009</pub-id><?supplied-pmid 23498916?><pub-id pub-id-type="pmid">23498916</pub-id></mixed-citation>
              </ref>
              <ref id="zoi211221r23">
                <label>23</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Liu</surname><given-names>X</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name><surname>Gutierrez</surname><given-names>JS</given-names></string-name>, <etal/></person-group>. <article-title>Disruption of a key ligand-H-bond network drives dissociative properties in vamorolone for Duchenne muscular dystrophy treatment</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2020</year>;<volume>117</volume>(<issue>39</issue>):<fpage>24285</fpage>-<lpage>24293</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.2006890117</pub-id><?supplied-pmid 32917814?><pub-id pub-id-type="pmid">32917814</pub-id></mixed-citation>
              </ref>
              <ref id="zoi211221r24">
                <label>24</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Heier</surname><given-names>CR</given-names></string-name>, <string-name><surname>Yu</surname><given-names>Q</given-names></string-name>, <string-name><surname>Fiorillo</surname><given-names>AA</given-names></string-name>, <etal/></person-group>. <article-title>Vamorolone targets dual nuclear receptors to treat inflammation and dystrophic cardiomyopathy</article-title>. <source>Life Sci Alliance</source>. <year>2019</year>;<volume>2</volume>(<issue>1</issue>):<fpage>1</fpage>-<lpage>16</lpage>. doi:<pub-id pub-id-type="doi">10.26508/lsa.201800186</pub-id><?supplied-pmid 30745312?><pub-id pub-id-type="pmid">30745312</pub-id></mixed-citation>
              </ref>
              <ref id="zoi211221r25">
                <label>25</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Conklin</surname><given-names>LS</given-names></string-name>, <string-name><surname>Damsker</surname><given-names>JM</given-names></string-name>, <string-name><surname>Hoffman</surname><given-names>EP</given-names></string-name>, <etal/></person-group>. <article-title>Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug</article-title>. <source>Pharmacol Res</source>. <year>2018</year>;<volume>136</volume>:<fpage>140</fpage>-<lpage>150</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.phrs.2018.09.007</pub-id><?supplied-pmid 30219580?><pub-id pub-id-type="pmid">30219580</pub-id></mixed-citation>
              </ref>
              <ref id="zoi211221r26">
                <label>26</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Hoffman</surname><given-names>EP</given-names></string-name>, <string-name><surname>Schwartz</surname><given-names>BD</given-names></string-name>, <string-name><surname>Mengle-Gaw</surname><given-names>LJ</given-names></string-name>, <etal/>; <collab>Cooperative International Neuromuscular Research Group</collab></person-group>. <article-title>Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function</article-title>. <source>Neurology</source>. <year>2019</year>;<volume>93</volume>(<issue>13</issue>):<fpage>e1312</fpage>-<lpage>e1323</lpage>. doi:<pub-id pub-id-type="doi">10.1212/WNL.0000000000008168</pub-id><?supplied-pmid 31451516?><pub-id pub-id-type="pmid">31451516</pub-id></mixed-citation>
              </ref>
              <ref id="zoi211221r27">
                <label>27</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Smith</surname><given-names>EC</given-names></string-name>, <string-name><surname>Conklin</surname><given-names>LS</given-names></string-name>, <string-name><surname>Hoffman</surname><given-names>EP</given-names></string-name>, <etal/>; <collab>CINRG VBP15 and DNHS Investigators</collab></person-group>. <article-title>Efficacy and safety of vamorolone in Duchenne muscular dystrophy: an 18-month interim analysis of a non-randomized open-label extension study</article-title>. <source>PLoS Med</source>. <year>2020</year>;<volume>17</volume>(<issue>9</issue>):<elocation-id>e1003222</elocation-id>. doi:<pub-id pub-id-type="doi">10.1371/journal.pmed.1003222</pub-id><?supplied-pmid 32956407?><pub-id pub-id-type="pmid">32956407</pub-id></mixed-citation>
              </ref>
              <ref id="zoi211221r28">
                <label>28</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>McDonald</surname><given-names>CM</given-names></string-name>, <string-name><surname>Henricson</surname><given-names>EK</given-names></string-name>, <string-name><surname>Abresch</surname><given-names>RT</given-names></string-name>, <etal/>; <collab>CINRG Investigators</collab></person-group>. <article-title>The cooperative international neuromuscular research group Duchenne natural history study—a longitudinal investigation in the era of glucocorticoid therapy: design of protocol and the methods used</article-title>. <source>Muscle Nerve</source>. <year>2013</year>;<volume>48</volume>(<issue>1</issue>):<fpage>32</fpage>-<lpage>54</lpage>. doi:<pub-id pub-id-type="doi">10.1002/mus.23807</pub-id><?supplied-pmid 23677550?><pub-id pub-id-type="pmid">23677550</pub-id></mixed-citation>
              </ref>
              <ref id="zoi211221r29">
                <label>29</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Henricson</surname><given-names>EK</given-names></string-name>, <string-name><surname>Abresch</surname><given-names>RT</given-names></string-name>, <string-name><surname>Cnaan</surname><given-names>A</given-names></string-name>, <etal/>; <collab>CINRG Investigators</collab></person-group>. <article-title>The cooperative international neuromuscular research group Duchenne natural history study: glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing and other commonly used clinical trial outcome measures</article-title>. <source>Muscle Nerve</source>. <year>2013</year>;<volume>48</volume>(<issue>1</issue>):<fpage>55</fpage>-<lpage>67</lpage>. doi:<pub-id pub-id-type="doi">10.1002/mus.23808</pub-id><?supplied-pmid 23649481?><pub-id pub-id-type="pmid">23649481</pub-id></mixed-citation>
              </ref>
              <ref id="zoi211221r30">
                <label>30</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>McDonald</surname><given-names>CM</given-names></string-name>, <string-name><surname>Henricson</surname><given-names>EK</given-names></string-name>, <string-name><surname>Abresch</surname><given-names>RT</given-names></string-name>, <etal/>; <collab>CINRG Investigators</collab></person-group>. <article-title>Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study</article-title>. <source>Lancet</source>. <year>2018</year>;<volume>391</volume>(<issue>10119</issue>):<fpage>451</fpage>-<lpage>461</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(17)32160-8</pub-id><?supplied-pmid 29174484?><pub-id pub-id-type="pmid">29174484</pub-id></mixed-citation>
              </ref>
              <ref id="zoi211221r31">
                <label>31</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Iacus</surname><given-names>SM</given-names></string-name>, <string-name><surname>King</surname><given-names>G</given-names></string-name>, <string-name><surname>Porro</surname><given-names>G</given-names></string-name></person-group>. <article-title>Multivariate matching methods that are monotonic imbalance bounding</article-title>. <source>J Am Stat Assoc.</source><year>2011</year>;<volume>106</volume>(<issue>493</issue>):<fpage>345</fpage>-<lpage>361</lpage>. doi:<pub-id pub-id-type="doi">10.1198/jasa.2011.tm09599</pub-id></mixed-citation>
              </ref>
              <ref id="zoi211221r32">
                <label>32</label>
                <mixed-citation publication-type="webpage"><person-group><string-name><surname>Iacus</surname><given-names>SM</given-names></string-name>, <string-name><surname>King</surname><given-names>G</given-names></string-name>, <string-name><surname>Porro</surname><given-names>G</given-names></string-name>, <string-name><surname>Nielsen</surname><given-names>R</given-names></string-name></person-group>. CEM: coarsened exact matching. The Comprehensive R Archive Network. Accessed December 8, 2021. <ext-link xlink:href="https://cran.r-project.org/package=cem" ext-link-type="uri">https://cran.r-project.org/package=cem</ext-link></mixed-citation>
              </ref>
              <ref id="zoi211221r33">
                <label>33</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Ricotti</surname><given-names>V</given-names></string-name>, <string-name><surname>Ridout</surname><given-names>DA</given-names></string-name>, <string-name><surname>Pane</surname><given-names>M</given-names></string-name>, <etal/>; <collab>UK NorthStar Clinical Network</collab></person-group>. <article-title>The NorthStar Ambulatory Assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials</article-title>. <source>J Neurol Neurosurg Psychiatry</source>. <year>2016</year>;<volume>87</volume>(<issue>2</issue>):<fpage>149</fpage>-<lpage>155</lpage>. doi:<pub-id pub-id-type="doi">10.1136/jnnp-2014-309405</pub-id><?supplied-pmid 25733532?><pub-id pub-id-type="pmid">25733532</pub-id></mixed-citation>
              </ref>
              <ref id="zoi211221r34">
                <label>34</label>
                <mixed-citation publication-type="webpage"><person-group><collab>Centers for Disease Control and Prevention</collab></person-group>. Percentile data files with LMS values. National Center for Health Statistics. Accessed December 8, 2021. <ext-link xlink:href="https://www.cdc.gov/growthcharts/percentile_data_files.htm" ext-link-type="uri">https://www.cdc.gov/growthcharts/percentile_data_files.htm</ext-link></mixed-citation>
              </ref>
              <ref id="zoi211221r35">
                <label>35</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Brooke</surname><given-names>MH</given-names></string-name>, <string-name><surname>Griggs</surname><given-names>RC</given-names></string-name>, <string-name><surname>Mendell</surname><given-names>JR</given-names></string-name>, <string-name><surname>Fenichel</surname><given-names>GM</given-names></string-name>, <string-name><surname>Shumate</surname><given-names>JB</given-names></string-name>, <string-name><surname>Pellegrino</surname><given-names>RJ</given-names></string-name></person-group>. <article-title>Clinical trial in Duchenne dystrophy: I. the design of the protocol</article-title>. <source>Muscle Nerve</source>. <year>1981</year>;<volume>4</volume>(<issue>3</issue>):<fpage>186</fpage>-<lpage>197</lpage>. doi:<pub-id pub-id-type="doi">10.1002/mus.880040304</pub-id><?supplied-pmid 7017401?><pub-id pub-id-type="pmid">7017401</pub-id></mixed-citation>
              </ref>
              <ref id="zoi211221r36">
                <label>36</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>McDonald</surname><given-names>CM</given-names></string-name>, <string-name><surname>Henricson</surname><given-names>EK</given-names></string-name>, <string-name><surname>Han</surname><given-names>JJ</given-names></string-name>, <etal/></person-group>. <article-title>The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy</article-title>. <source>Muscle Nerve</source>. <year>2010</year>;<volume>41</volume>(<issue>4</issue>):<fpage>500</fpage>-<lpage>510</lpage>. doi:<pub-id pub-id-type="doi">10.1002/mus.21544</pub-id><?supplied-pmid 19941337?><pub-id pub-id-type="pmid">19941337</pub-id></mixed-citation>
              </ref>
              <ref id="zoi211221r37">
                <label>37</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Scott</surname><given-names>E</given-names></string-name>, <string-name><surname>Eagle</surname><given-names>M</given-names></string-name>, <string-name><surname>Mayhew</surname><given-names>A</given-names></string-name>, <etal/>; <collab>North Star Clinical Network for Paediatric Neuromuscular Disease</collab></person-group>. <article-title>Development of a functional assessment scale for ambulatory boys with Duchenne muscular dystrophy</article-title>. <source>Physiother Res Int</source>. <year>2012</year>;<volume>17</volume>(<issue>2</issue>):<fpage>101</fpage>-<lpage>109</lpage>. doi:<pub-id pub-id-type="doi">10.1002/pri.520</pub-id><?supplied-pmid 21954141?><pub-id pub-id-type="pmid">21954141</pub-id></mixed-citation>
              </ref>
              <ref id="zoi211221r38">
                <label>38</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Escolar</surname><given-names>DM</given-names></string-name>, <string-name><surname>Henricson</surname><given-names>EK</given-names></string-name>, <string-name><surname>Mayhew</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>Clinical evaluator reliability for quantitative and manual muscle testing measures of strength in children</article-title>. <source>Muscle Nerve</source>. <year>2001</year>;<volume>24</volume>(<issue>6</issue>):<fpage>787</fpage>-<lpage>793</lpage>. doi:<pub-id pub-id-type="doi">10.1002/mus.1070</pub-id><?supplied-pmid 11360262?><pub-id pub-id-type="pmid">11360262</pub-id></mixed-citation>
              </ref>
              <ref id="zoi211221r39">
                <label>39</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Dang</surname><given-names>UJ</given-names></string-name>, <string-name><surname>Ziemba</surname><given-names>M</given-names></string-name>, <string-name><surname>Clemens</surname><given-names>PR</given-names></string-name>, <string-name><surname>Hathout</surname><given-names>Y</given-names></string-name>, <string-name><surname>Conklin</surname><given-names>LS</given-names></string-name>, <string-name><surname>Hoffman</surname><given-names>EP</given-names></string-name>; <collab>CINRG Vamorolone 002/003 Investigators</collab></person-group>. <article-title>Serum biomarkers associated with baseline clinical severity in young steroid-naïve Duchenne muscular dystrophy boys</article-title>. <source>Hum Mol Genet</source>. <year>2020</year>;<volume>29</volume>(<issue>15</issue>):<fpage>2481</fpage>-<lpage>2495</lpage>. doi:<pub-id pub-id-type="doi">10.1093/hmg/ddaa132</pub-id><?supplied-pmid 32592467?><pub-id pub-id-type="pmid">32592467</pub-id></mixed-citation>
              </ref>
              <ref id="zoi211221r40">
                <label>40</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>McDonald</surname><given-names>CM</given-names></string-name>, <string-name><surname>McDonald</surname><given-names>DA</given-names></string-name>, <string-name><surname>Bagley</surname><given-names>A</given-names></string-name>, <etal/></person-group>. <article-title>Relationship between clinical outcome measures and parent proxy reports of health-related quality of life in ambulatory children with Duchenne muscular dystrophy</article-title>. <source>J Child Neurol</source>. <year>2010</year>;<volume>25</volume>(<issue>9</issue>):<fpage>1130</fpage>-<lpage>1144</lpage>. doi:<pub-id pub-id-type="doi">10.1177/0883073810371509</pub-id><?supplied-pmid 20558672?><pub-id pub-id-type="pmid">20558672</pub-id></mixed-citation>
              </ref>
              <ref id="zoi211221r41">
                <label>41</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>McDonald</surname><given-names>CM</given-names></string-name>, <string-name><surname>Campbell</surname><given-names>C</given-names></string-name>, <string-name><surname>Torricelli</surname><given-names>RE</given-names></string-name>, <etal/>; <collab>Clinical Evaluator Training Group</collab>; <collab>ACT DMD Study Group</collab></person-group>. <article-title>Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial</article-title>. <source>Lancet</source>. <year>2017</year>;<volume>390</volume>(<issue>10101</issue>):<fpage>1489</fpage>-<lpage>1498</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(17)31611-2</pub-id><?supplied-pmid 28728956?><pub-id pub-id-type="pmid">28728956</pub-id></mixed-citation>
              </ref>
              <ref id="zoi211221r42">
                <label>42</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Fay</surname><given-names>MP</given-names></string-name>, <string-name><surname>Shaw</surname><given-names>PA</given-names></string-name></person-group>. <article-title>Exact and asymptotic weighted logrank tests for interval censored data: the interval R package</article-title>. <source>J Stat Softw</source>. <year>2010</year>;<volume>36</volume>(<issue>2</issue>):<fpage>io2</fpage>. doi:<pub-id pub-id-type="doi">10.18637/jss.v036.i02</pub-id><?supplied-pmid 25285054?><pub-id pub-id-type="pmid">25285054</pub-id></mixed-citation>
              </ref>
              <ref id="zoi211221r43">
                <label>43</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Bates</surname><given-names>D</given-names></string-name>, <string-name><surname>Mächler</surname><given-names>M</given-names></string-name>, <string-name><surname>Bolker</surname><given-names>BM</given-names></string-name>, <string-name><surname>Walker</surname><given-names>S</given-names></string-name></person-group>. <article-title>Fitting linear mixed-effects models using lme4</article-title>. <source>J Stat Softw.</source><year>2015</year>;<volume>67</volume>(<issue>1</issue>):<fpage>1</fpage>-<lpage>48</lpage>. doi:<pub-id pub-id-type="doi">10.18637/jss.v067.i01</pub-id></mixed-citation>
              </ref>
              <ref id="zoi211221r44">
                <label>44</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Kuznetsova</surname><given-names>A</given-names></string-name>, <string-name><surname>Brockhoff</surname><given-names>PB</given-names></string-name>, <string-name><surname>Christensen</surname><given-names>RHB</given-names></string-name></person-group>. <article-title>lmerTest Package: Tests in Linear Mixed Effects Models</article-title>. <source>J Stat Softw.</source><year>2017</year>;<volume>82</volume>(<issue>13</issue>). doi:<pub-id pub-id-type="doi">10.18637/jss.v082.i13</pub-id></mixed-citation>
              </ref>
              <ref id="zoi211221r45">
                <label>45</label>
                <mixed-citation publication-type="webpage"><person-group><string-name><surname>Lüdecke</surname><given-names>D.</given-names></string-name></person-group> sjPlot—data visualization for statistics in social science. GitHub. Accessed December 8, 2021. <ext-link xlink:href="https://strengejacke.github.io/sjPlot/" ext-link-type="uri">https://strengejacke.github.io/sjPlot/</ext-link></mixed-citation>
              </ref>
              <ref id="zoi211221r46">
                <label>46</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Breheny</surname><given-names>P</given-names></string-name>, <string-name><surname>Burchett</surname><given-names>W.</given-names></string-name></person-group><article-title>Visualization of regression models using visreg</article-title>. <source>R J.</source><year>2017</year>;<volume>9</volume>(<issue>2</issue>):<fpage>56</fpage>-<lpage>71</lpage>. doi:<pub-id pub-id-type="doi">10.32614/RJ-2017-046</pub-id></mixed-citation>
              </ref>
              <ref id="zoi211221r47">
                <label>47</label>
                <mixed-citation publication-type="webpage"><person-group><string-name><surname>Raabe</surname><given-names>S.</given-names></string-name></person-group> Vistime: pretty timelines in R. R package version 1.2.1. The Comprehensive R Archive Network. Accessed December 8, 2021. <ext-link xlink:href="https://CRAN.R-project.org/package=vistime" ext-link-type="uri">https://CRAN.R-project.org/package=vistime</ext-link></mixed-citation>
              </ref>
              <ref id="zoi211221r48">
                <label>48</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Arora</surname><given-names>H</given-names></string-name>, <string-name><surname>Willcocks</surname><given-names>RJ</given-names></string-name>, <string-name><surname>Lott</surname><given-names>DJ</given-names></string-name>, <etal/></person-group>. <article-title>Longitudinal timed function tests in Duchenne muscular dystrophy: ImagingDMD cohort natural history</article-title>. <source>Muscle Nerve</source>. <year>2018</year>;<volume>58</volume>(<issue>5</issue>):<fpage>631</fpage>-<lpage>638</lpage>. doi:<pub-id pub-id-type="doi">10.1002/mus.26161</pub-id><?supplied-pmid 29742798?><pub-id pub-id-type="pmid">29742798</pub-id></mixed-citation>
              </ref>
              <ref id="zoi211221r49">
                <label>49</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Ward</surname><given-names>LM</given-names></string-name>, <string-name><surname>Weber</surname><given-names>DR</given-names></string-name></person-group>. <article-title>Growth, pubertal development, and skeletal health in boys with Duchenne muscular dystrophy</article-title>. <source>Curr Opin Endocrinol Diabetes Obes</source>. <year>2019</year>;<volume>26</volume>(<issue>1</issue>):<fpage>39</fpage>-<lpage>48</lpage>. doi:<pub-id pub-id-type="doi">10.1097/MED.0000000000000456</pub-id><?supplied-pmid 30507696?><pub-id pub-id-type="pmid">30507696</pub-id></mixed-citation>
              </ref>
              <ref id="zoi211221r50">
                <label>50</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Joseph</surname><given-names>S</given-names></string-name>, <string-name><surname>Wang</surname><given-names>C</given-names></string-name>, <string-name><surname>Bushby</surname><given-names>K</given-names></string-name>, <etal/>; <collab>UK NorthStar Clinical Network</collab></person-group>. <article-title>Fractures and linear growth in a nationwide cohort of boys with Duchenne muscular dystrophy with and without glucocorticoid treatment: results from the UK NorthStar database</article-title>. <source>JAMA Neurol</source>. <year>2019</year>;<volume>76</volume>(<issue>6</issue>):<fpage>701</fpage>-<lpage>709</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jamaneurol.2019.0242</pub-id><?supplied-pmid 30855644?><pub-id pub-id-type="pmid">30855644</pub-id></mixed-citation>
              </ref>
              <ref id="zoi211221r51">
                <label>51</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Wood</surname><given-names>CL</given-names></string-name>, <string-name><surname>Straub</surname><given-names>V</given-names></string-name>, <string-name><surname>Guglieri</surname><given-names>M</given-names></string-name>, <string-name><surname>Bushby</surname><given-names>K</given-names></string-name>, <string-name><surname>Cheetham</surname><given-names>T</given-names></string-name></person-group>. <article-title>Short stature and pubertal delay in Duchenne muscular dystrophy</article-title>. <source>Arch Dis Child</source>. <year>2016</year>;<volume>101</volume>(<issue>1</issue>):<fpage>101</fpage>-<lpage>106</lpage>. doi:<pub-id pub-id-type="doi">10.1136/archdischild-2015-308654</pub-id><?supplied-pmid 26141541?><pub-id pub-id-type="pmid">26141541</pub-id></mixed-citation>
              </ref>
              <ref id="zoi211221r52">
                <label>52</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Griggs</surname><given-names>RC</given-names></string-name>, <string-name><surname>Herr</surname><given-names>BE</given-names></string-name>, <string-name><surname>Reha</surname><given-names>A</given-names></string-name>, <etal/></person-group>. <article-title>Corticosteroids in Duchenne muscular dystrophy: major variations in practice</article-title>. <source>Muscle Nerve</source>. <year>2013</year>;<volume>48</volume>(<issue>1</issue>):<fpage>27</fpage>-<lpage>31</lpage>. doi:<pub-id pub-id-type="doi">10.1002/mus.23831</pub-id><?supplied-pmid 23483575?><pub-id pub-id-type="pmid">23483575</pub-id></mixed-citation>
              </ref>
            </ref-list>
            <notes notes-type="supplementary-material" id="note-ZOI211221-1">
              <supplementary-material id="note-ZOI211221-1-s" position="float" content-type="local-data">
                <label>Supplement 1.</label>
                <caption>
                  <p><bold>eTable 1.</bold> Comparison of Coarsened Exact Matched Participants in Duchenne Natural History Study (DNHS) and Higher-Dose VBP15 Long-term Extension (LTE) Study</p>
                  <p><bold>eTable 2.</bold> Pediatric Outcomes Data Collection Instrument (PODCI) Scores</p>
                  <p><bold>eTable 3.</bold> Quantitative Muscle Testing (QMT) Scores</p>
                  <p><bold>eTable 4.</bold> Adverse Events by Dose at Time of Event From 30 mo of Vamorolone Treatment</p>
                  <p><bold>eFigure 1.</bold> Patient-Level Dose Regimen Schematic</p>
                  <p><bold>eFigure 2.</bold> Timed Motor Function Comparisons of Vamorolone Long-term Extension vs Duchenne Natural History Study With Individual Trajectories</p>
                  <p><bold>eFigure 3.</bold> Body Mass Index <italic>z</italic> Score and Height Percentile Comparisons of Vamorolone Long-term Extension vs Duchenne Natural History Study With Individual Trajectories</p>
                  <p><bold>eAppendix 1.</bold> Duchenne Natural History Study Cohort External Comparison Workflow Plan</p>
                  <p><bold>eAppendix 2.</bold> NorthStar United Kingdom Network Cohort External Comparison Workflow Plan</p>
                  <p><bold>eAppendix 3.</bold> Supplemental Text on Statistical Analysis</p>
                </caption>
                <media xlink:href="jamanetwopen-e2144178-s001.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material position="float" content-type="local-data">
                <label>Supplement 2.</label>
                <caption>
                  <p>
Trial Protocol
</p>
                </caption>
                <media xlink:href="jamanetwopen-e2144178-s002.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material position="float" content-type="local-data">
                <label>Supplement 3.</label>
                <caption>
                  <p>
Group Authors
</p>
                </caption>
                <media xlink:href="jamanetwopen-e2144178-s003.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material position="float" content-type="local-data">
                <label>Supplement 4.</label>
                <caption>
                  <p>
Data Sharing Statement
</p>
                </caption>
                <media xlink:href="jamanetwopen-e2144178-s004.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </notes>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
